US11932672B2 - Fermentation process - Google Patents
Fermentation process Download PDFInfo
- Publication number
- US11932672B2 US11932672B2 US16/955,720 US201816955720A US11932672B2 US 11932672 B2 US11932672 B2 US 11932672B2 US 201816955720 A US201816955720 A US 201816955720A US 11932672 B2 US11932672 B2 US 11932672B2
- Authority
- US
- United States
- Prior art keywords
- nucleic acid
- promoter
- acid sequence
- bba
- bacteriocin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active, expires
Links
- 238000000855 fermentation Methods 0.000 title claims description 7
- 230000004151 fermentation Effects 0.000 title claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 214
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 137
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 137
- 230000000813 microbial effect Effects 0.000 claims abstract description 119
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 73
- 230000002068 genetic effect Effects 0.000 claims abstract description 73
- 238000004519 manufacturing process Methods 0.000 claims abstract description 28
- 230000008901 benefit Effects 0.000 claims abstract description 21
- 108010062877 Bacteriocins Proteins 0.000 claims description 212
- 230000036039 immunity Effects 0.000 claims description 129
- 210000004027 cell Anatomy 0.000 claims description 95
- 108090000623 proteins and genes Proteins 0.000 claims description 74
- 238000000034 method Methods 0.000 claims description 71
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 62
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 56
- 229920001184 polypeptide Polymers 0.000 claims description 46
- 108010073254 Colicins Proteins 0.000 claims description 26
- 239000013612 plasmid Substances 0.000 claims description 26
- 230000001939 inductive effect Effects 0.000 claims description 18
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 17
- 210000004899 c-terminal region Anatomy 0.000 claims description 16
- 241000894006 Bacteria Species 0.000 claims description 13
- 238000012258 culturing Methods 0.000 claims description 13
- 241000195493 Cryptophyta Species 0.000 claims description 11
- 230000001131 transforming effect Effects 0.000 claims description 9
- 239000002243 precursor Substances 0.000 claims description 7
- 241000233866 Fungi Species 0.000 claims description 6
- 239000002551 biofuel Substances 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 3
- 239000002207 metabolite Substances 0.000 claims description 3
- 239000002028 Biomass Substances 0.000 claims description 2
- 229960000074 biopharmaceutical Drugs 0.000 claims description 2
- 150000002632 lipids Chemical class 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 239000000047 product Substances 0.000 description 58
- 241000588724 Escherichia coli Species 0.000 description 56
- 230000000694 effects Effects 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 38
- 102000004169 proteins and genes Human genes 0.000 description 38
- 239000013598 vector Substances 0.000 description 31
- 239000000203 mixture Substances 0.000 description 26
- 241000194032 Enterococcus faecalis Species 0.000 description 24
- 241000194031 Enterococcus faecium Species 0.000 description 22
- 239000001963 growth medium Substances 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 21
- 235000014469 Bacillus subtilis Nutrition 0.000 description 20
- 229940024606 amino acid Drugs 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 241000894007 species Species 0.000 description 19
- 230000001105 regulatory effect Effects 0.000 description 18
- 241000194035 Lactococcus lactis Species 0.000 description 17
- 235000014897 Streptococcus lactis Nutrition 0.000 description 17
- 240000006024 Lactobacillus plantarum Species 0.000 description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 description 16
- CTBBEXWJRAPJIZ-VHPBLNRZSA-N (1S,2S,3S,6R,8R,9S,10R)-2-benzoyl-1,3,8,10-tetrahydroxy-9-(4-methoxy-6-oxopyran-2-yl)-5-oxatricyclo[4.3.1.03,8]decan-4-one Chemical compound O1C(=O)C=C(OC)C=C1[C@H]1[C@]([C@@H]2O)(O)[C@H](C(=O)C=3C=CC=CC=3)[C@@]3(O)C(=O)O[C@@H]2C[C@]31O CTBBEXWJRAPJIZ-VHPBLNRZSA-N 0.000 description 15
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 15
- 230000021615 conjugation Effects 0.000 description 14
- 229940032049 enterococcus faecalis Drugs 0.000 description 14
- 244000005700 microbiome Species 0.000 description 14
- 108091033319 polynucleotide Proteins 0.000 description 14
- 102000040430 polynucleotide Human genes 0.000 description 14
- 239000002157 polynucleotide Substances 0.000 description 14
- 241000206600 Carnobacterium maltaromaticum Species 0.000 description 13
- 230000003247 decreasing effect Effects 0.000 description 13
- CTBBEXWJRAPJIZ-UHFFFAOYSA-N Enterocin Natural products O1C(=O)C=C(OC)C=C1C1C(C2O)(O)C(C(=O)C=3C=CC=CC=3)C3(O)C(=O)OC2CC31O CTBBEXWJRAPJIZ-UHFFFAOYSA-N 0.000 description 12
- 241000194041 Lactococcus lactis subsp. lactis Species 0.000 description 12
- 235000014969 Streptococcus diacetilactis Nutrition 0.000 description 12
- 239000003242 anti bacterial agent Substances 0.000 description 12
- 229940088710 antibiotic agent Drugs 0.000 description 11
- 230000035897 transcription Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 108020004414 DNA Proteins 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 108010079904 microcin Proteins 0.000 description 10
- 241001099134 unclassified Bacillus Species 0.000 description 10
- 241000193830 Bacillus <bacterium> Species 0.000 description 9
- 244000063299 Bacillus subtilis Species 0.000 description 9
- 241000206593 Carnobacterium divergens Species 0.000 description 9
- 241000132152 Polymyxa Species 0.000 description 9
- 125000003275 alpha amino acid group Chemical group 0.000 description 9
- 238000010276 construction Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 108091026890 Coding region Proteins 0.000 description 8
- 241000192700 Cyanobacteria Species 0.000 description 8
- 241001134659 Lactobacillus curvatus Species 0.000 description 8
- 241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 8
- 235000014962 Streptococcus cremoris Nutrition 0.000 description 8
- 230000006870 function Effects 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 108091005461 Nucleic proteins Chemical group 0.000 description 7
- 241001494489 Thielavia Species 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000009089 cytolysis Effects 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 230000007613 environmental effect Effects 0.000 description 7
- 210000001990 heterocyst Anatomy 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 7
- 101150016512 luxR gene Proteins 0.000 description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 6
- 101000655617 Bacillus cereus (strain ATCC 14579 / DSM 31 / CCUG 7414 / JCM 2152 / NBRC 15305 / NCIMB 9373 / NCTC 2599 / NRRL B-3711) Thiocillin Proteins 0.000 description 6
- 241000223218 Fusarium Species 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 6
- 241000186612 Lactobacillus sakei Species 0.000 description 6
- 108091081024 Start codon Proteins 0.000 description 6
- 230000004927 fusion Effects 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 5
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 5
- 240000001046 Lactobacillus acidophilus Species 0.000 description 5
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 5
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 5
- 241000194105 Paenibacillus polymyxa Species 0.000 description 5
- 241000191963 Staphylococcus epidermidis Species 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000001276 controlling effect Effects 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 5
- 108010066097 lactococcin A Proteins 0.000 description 5
- 238000006386 neutralization reaction Methods 0.000 description 5
- 230000004481 post-translational protein modification Effects 0.000 description 5
- 230000002103 transcriptional effect Effects 0.000 description 5
- 230000014621 translational initiation Effects 0.000 description 5
- UHPMCKVQTMMPCG-UHFFFAOYSA-N 5,8-dihydroxy-2-methoxy-6-methyl-7-(2-oxopropyl)naphthalene-1,4-dione Chemical compound CC1=C(CC(C)=O)C(O)=C2C(=O)C(OC)=CC(=O)C2=C1O UHPMCKVQTMMPCG-UHFFFAOYSA-N 0.000 description 4
- 241000194108 Bacillus licheniformis Species 0.000 description 4
- 241000520134 Enterococcus mundtii Species 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 4
- 101100273253 Rhizopus niveus RNAP gene Proteins 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 4
- 230000003213 activating effect Effects 0.000 description 4
- 108091008053 gene clusters Proteins 0.000 description 4
- 108010086913 mundticin Proteins 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 101000640052 Bacillus subtilis (strain 168) Subtilosin-A Proteins 0.000 description 3
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 3
- 241000123346 Chrysosporium Species 0.000 description 3
- 101710193010 Colicin-E1 immunity protein Proteins 0.000 description 3
- 241000221779 Fusarium sambucinum Species 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 3
- 241000186606 Lactobacillus gasseri Species 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- 102100025169 Max-binding protein MNT Human genes 0.000 description 3
- 101150026476 PAO1 gene Proteins 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 241000235648 Pichia Species 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 3
- 241000607142 Salmonella Species 0.000 description 3
- 241000194019 Streptococcus mutans Species 0.000 description 3
- 241000194024 Streptococcus salivarius Species 0.000 description 3
- 241000194020 Streptococcus thermophilus Species 0.000 description 3
- 241000194054 Streptococcus uberis Species 0.000 description 3
- 241000187747 Streptomyces Species 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 229940097012 bacillus thuringiensis Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000022131 cell cycle Effects 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000002538 fungal effect Effects 0.000 description 3
- 108010070411 gardimycin Proteins 0.000 description 3
- 150000002333 glycines Chemical class 0.000 description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 108010093128 lactacin F Proteins 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- FRJVEVHOMWPHHN-UBTJVNBSSA-N microcin j25 Chemical compound C([C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(O)=O)C(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H]1NC(=O)[C@@H]2CCCN2C(=O)[C@H](C(C)C)NC(=O)[C@H](CC=2NC=NC=2)NC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)CNC(=O)CC1)C1=CC=CC=C1 FRJVEVHOMWPHHN-UBTJVNBSSA-N 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- ZRUMXHGBGLWVDT-SJMRFLIKSA-N pediocin pa 1 Chemical compound C([C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@@H](CC=2NC=NC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N1)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H]1NC(=O)[C@H](CO)NC(=O)[C@H](CC=2NC=NC=2)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(O)=O)C1=CN=CN1 ZRUMXHGBGLWVDT-SJMRFLIKSA-N 0.000 description 3
- 230000001124 posttranscriptional effect Effects 0.000 description 3
- 230000001323 posttranslational effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 229940115922 streptococcus uberis Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KKOBSYCWZKDJLN-UHFFFAOYSA-N thuricin cd Chemical compound N1C(=O)C(CO)NC(=O)C(C)NC(=O)C(SC2)(C)NC(=O)C(C)NC(=O)C(CC=3C=CC=CC=3)NC(=O)C(CCC(O)=O)NC(=O)C(SC3)(C(C)O)NC(=O)CNC(=O)C(C(C)C)NC(=O)CNC(=O)CNC(=O)C(CO)NC(=O)C(C)NC(=O)C(CC(C)C)NC(=O)C3NC(=O)C(C(C)C)NC(=O)C(C(C)O)NC(=O)CNC(=O)C2NC(=O)C(C)NC(=O)CNC(=O)C(C(C)C)NC(=O)C(NC(=O)C(C)NC(=O)C(NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)CN)C(C)C)CSC1(CC=1C=CC(O)=CC=1)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=CC=C1 KKOBSYCWZKDJLN-UHFFFAOYSA-N 0.000 description 3
- 108091006107 transcriptional repressors Proteins 0.000 description 3
- 241000308619 unclassified Staphylococcus Species 0.000 description 3
- 241000470638 'Nostoc azollae' 0708 Species 0.000 description 2
- MXABZXILAJGOTL-AUYMZICSSA-N (2S)-N-[(2S)-1-[(2S)-1-[(2S,3S)-1-[(2S)-1-[2-[(2S)-1,3-dihydroxy-1-[(E)-1-hydroxy-1-[(2S,3S)-1-hydroxy-3-methyl-1-[[(2Z,6S,9S,12R)-5,8,11-trihydroxy-9-(2-methylpropyl)-6-propan-2-yl-1-thia-4,7,10-triazacyclotrideca-2,4,7,10-tetraen-12-yl]imino]pentan-2-yl]iminobut-2-en-2-yl]iminopropan-2-yl]imino-2-hydroxyethyl]imino-1,5-dihydroxy-5-iminopentan-2-yl]imino-1-hydroxy-3-methylpentan-2-yl]imino-1-hydroxy-3-methylbutan-2-yl]imino-1-hydroxy-3-phenylpropan-2-yl]-2-[[(2S)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[(Z)-2-[[(2S)-2-[[[(2S)-1-[(Z)-2-[[(2S)-2-(dimethylamino)-1-hydroxypropylidene]amino]but-2-enoyl]pyrrolidin-2-yl]-hydroxymethylidene]amino]-1-hydroxypropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-phenylpropylidene]amino]-1-hydroxybut-2-enylidene]amino]-1-hydroxy-3-methylbutylidene]amino]-1-hydroxypropylidene]amino]pentanediimidic acid Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@@H](\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)[C@H](C)\N=C(/O)[C@@H](\N=C(/O)\C(=C\C)\N=C(/O)[C@H](Cc1ccccc1)\N=C(/O)\C(=C\C)\N=C(/O)[C@H](C)\N=C(/O)[C@@H]1CCCN1C(=O)\C(=C\C)\N=C(/O)[C@H](C)N(C)C)C(C)C)C(C)C)C(\O)=N\[C@@H](CCC(O)=N)C(\O)=N\C\C(O)=N\[C@@H](CO)C(\O)=N\C(=C\C)\C(\O)=N\[C@@H]([C@@H](C)CC)C(\O)=N\[C@H]1CS\C=C/N=C(O)\[C@@H](\N=C(O)/[C@H](CC(C)C)\N=C1\O)C(C)C MXABZXILAJGOTL-AUYMZICSSA-N 0.000 description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
- CUHKVBVNLQPDQC-UHFFFAOYSA-N 3-[2,4,6,8-tetramethyl-4,6,8-tris(3-prop-2-enoyloxypropyl)-1,3,5,7,2,4,6,8-tetraoxatetrasilocan-2-yl]propyl prop-2-enoate Chemical compound C=CC(=O)OCCC[Si]1(C)O[Si](C)(CCCOC(=O)C=C)O[Si](C)(CCCOC(=O)C=C)O[Si](C)(CCCOC(=O)C=C)O1 CUHKVBVNLQPDQC-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 102100034035 Alcohol dehydrogenase 1A Human genes 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- 241001079721 Bacillus cereus 95/8201 Species 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 2
- 101001138050 Bacillus licheniformis (strain ATCC 14580 / DSM 13 / JCM 2505 / CCUG 7422 / NBRC 12200 / NCIMB 9375 / NCTC 10341 / NRRL NRS-1264 / Gibson 46) Lantibiotic lichenicidin A2 Proteins 0.000 description 2
- 108700016166 Bacillus subtilis sboA Proteins 0.000 description 2
- 241000722885 Brettanomyces Species 0.000 description 2
- 241000605900 Butyrivibrio fibrisolvens Species 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 241001660259 Cereus <cactus> Species 0.000 description 2
- 108700010070 Codon Usage Proteins 0.000 description 2
- 101710158752 Colicin-E5 Proteins 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- 241000159506 Cyanothece Species 0.000 description 2
- 108010069514 Cyclic Peptides Proteins 0.000 description 2
- 102000001189 Cyclic Peptides Human genes 0.000 description 2
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
- 241000701867 Enterobacteria phage T7 Species 0.000 description 2
- 101710172817 Enterocin E-760 Proteins 0.000 description 2
- 101710178816 Enterocin-HF Proteins 0.000 description 2
- 241000520130 Enterococcus durans Species 0.000 description 2
- 241000194029 Enterococcus hirae Species 0.000 description 2
- 241001495410 Enterococcus sp. Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 101001018328 Escherichia coli Bacteriocin microcin B17 Proteins 0.000 description 2
- 101000998562 Escherichia coli Colicin-E3 immunity protein Proteins 0.000 description 2
- 101001039716 Escherichia coli Microcin N Proteins 0.000 description 2
- 241000567163 Fusarium cerealis Species 0.000 description 2
- 241000146406 Fusarium heterosporum Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 101000892220 Geobacillus thermodenitrificans (strain NG80-2) Long-chain-alcohol dehydrogenase 1 Proteins 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000204988 Haloferax mediterranei Species 0.000 description 2
- 101000780443 Homo sapiens Alcohol dehydrogenase 1A Proteins 0.000 description 2
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 2
- 101710097900 Iota-carrageenase Proteins 0.000 description 2
- 241000588747 Klebsiella pneumoniae Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 235000013967 Lactobacillus helveticus Nutrition 0.000 description 2
- 241001468157 Lactobacillus johnsonii Species 0.000 description 2
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 2
- 241000194040 Lactococcus garvieae Species 0.000 description 2
- 101710140677 Lambda-carrageenase Proteins 0.000 description 2
- 101710173438 Late L2 mu core protein Proteins 0.000 description 2
- 241000192131 Leuconostoc gelidum Species 0.000 description 2
- 241001468196 Leuconostoc pseudomesenteroides Species 0.000 description 2
- 101710143441 Microcin E492 Proteins 0.000 description 2
- 108010053775 Nisin Proteins 0.000 description 2
- NVNLLIYOARQCIX-MSHCCFNRSA-N Nisin Chemical compound N1C(=O)[C@@H](CC(C)C)NC(=O)C(=C)NC(=O)[C@@H]([C@H](C)CC)NC(=O)[C@@H](NC(=O)C(=C/C)/NC(=O)[C@H](N)[C@H](C)CC)CSC[C@@H]1C(=O)N[C@@H]1C(=O)N2CCC[C@@H]2C(=O)NCC(=O)N[C@@H](C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(NCC(=O)N[C@H](C)C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCSC)C(=O)NCC(=O)N[C@H](CS[C@@H]2C)C(=O)N[C@H](CC(N)=O)C(=O)N[C@H](CCSC)C(=O)N[C@H](CCCCN)C(=O)N[C@@H]2C(N[C@H](C)C(=O)N[C@@H]3C(=O)N[C@@H](C(N[C@H](CC=4NC=NC=4)C(=O)N[C@H](CS[C@@H]3C)C(=O)N[C@H](CO)C(=O)N[C@H]([C@H](C)CC)C(=O)N[C@H](CC=3NC=NC=3)C(=O)N[C@H](C(C)C)C(=O)NC(=C)C(=O)N[C@H](CCCCN)C(O)=O)=O)CS[C@@H]2C)=O)=O)CS[C@@H]1C NVNLLIYOARQCIX-MSHCCFNRSA-N 0.000 description 2
- 241000192656 Nostoc Species 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 241000179039 Paenibacillus Species 0.000 description 2
- 241000588702 Pectobacterium carotovorum subsp. carotovorum Species 0.000 description 2
- 108010080032 Pediocins Proteins 0.000 description 2
- 241000191998 Pediococcus acidilactici Species 0.000 description 2
- 101710188315 Protein X Proteins 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 241000235346 Schizosaccharomyces Species 0.000 description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000194049 Streptococcus equinus Species 0.000 description 2
- 241000187180 Streptomyces sp. Species 0.000 description 2
- 108700009124 Transcription Initiation Site Proteins 0.000 description 2
- 241000970911 Trichormus variabilis ATCC 29413 Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 108010007559 alirin B1 Proteins 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 229940054340 bacillus coagulans Drugs 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 108010016445 cyanobactins Proteins 0.000 description 2
- 108010041566 cypemycin Proteins 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 108010032688 epilancin 15X Proteins 0.000 description 2
- 239000003337 fertilizer Substances 0.000 description 2
- LAWKVNVCUPIOMG-HWWYPGLISA-N gardimycin Chemical compound C1=CC=C2C(C[C@H](C(=O)NCC(=O)N[C@H](CO)C(=O)N[C@H](C)C(=O)NCC(=O)N[C@H](CC)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(O)=O)C(C)C)NC(=O)[C@@H](NC(=O)[C@@H](C)NC(=O)[C@@H](CC)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)N)[C@@H](C)CC)C(C)C)=CNC2=C1 LAWKVNVCUPIOMG-HWWYPGLISA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 239000003999 initiator Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 108010066110 lactococcin B Proteins 0.000 description 2
- 108010066379 lactococcin G Proteins 0.000 description 2
- VSKYMPAGYGCTFA-PQAXMVAFSA-N mature microcin B18 zwitterion Chemical compound CC[C@H](C)[C@H](\N=C(/O)[C@H](Cc1cnc[nH]1)\N=C(/O)[C@H](CO)\N=C(/O)C\N=C(/O)c1coc(C\N=C(/O)C\N=C(/O)c2coc(C\N=C(/O)C\N=C(/O)[C@H](CC(O)=N)\N=C(/O)C\N=C(/O)C\N=C(/O)c3coc(n3)-c3csc(C\N=C(/O)[C@H](CC(O)=N)\N=C(/O)[C@H](CO)\N=C(/O)c4csc(C\N=C(/O)C\N=C(/O)c5csc(C\N=C(/O)C\N=C(/O)C\N=C(/O)[C@H](CCC(O)=N)\N=C(/O)C\N=C(/O)C\N=C(/O)c6csc(n6)-c6coc(C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)C\N=C(/O)[C@@H](\N=C(/O)C\N=C(/O)[C@@H](N)C(C)C)[C@@H](C)CC)n6)n5)n4)n3)n2)n1)C(O)=O VSKYMPAGYGCTFA-PQAXMVAFSA-N 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108010067215 mersacidin Proteins 0.000 description 2
- 230000037353 metabolic pathway Effects 0.000 description 2
- XJAJBFWPYSQCKP-UHFFFAOYSA-N methyl 2-(6,7-dimethyl-3-oxo-4h-quinoxalin-2-yl)-4-(4-methoxy-2-nitroanilino)-3,4-dioxobutanoate Chemical compound N=1C2=CC(C)=C(C)C=C2NC(=O)C=1C(C(=O)OC)C(=O)C(=O)NC1=CC=C(OC)C=C1[N+]([O-])=O XJAJBFWPYSQCKP-UHFFFAOYSA-N 0.000 description 2
- 238000009629 microbiological culture Methods 0.000 description 2
- 108010001459 microcin H47 Proteins 0.000 description 2
- 108010073681 mutacin 1140 Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 description 2
- 239000004309 nisin Substances 0.000 description 2
- 235000010297 nisin Nutrition 0.000 description 2
- 101150008884 osmY gene Proteins 0.000 description 2
- 108010049023 pediocin PA-1 Proteins 0.000 description 2
- 230000000243 photosynthetic effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 108010062124 pyocin S1 Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 210000003705 ribosome Anatomy 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 108700018795 salivaricin A Proteins 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 108010037687 staphylococcin Proteins 0.000 description 2
- 108010045452 sublancin 168 Proteins 0.000 description 2
- NRQODXJXWWUXFE-LYQFAKRDSA-N subtilosin a Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]1N(C(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)CN)[C@@H](C)O)[C@@H](C)CC)C(C)C)CCC1 NRQODXJXWWUXFE-LYQFAKRDSA-N 0.000 description 2
- 108010067167 thuricin Proteins 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 108010062785 trifolitoxin Proteins 0.000 description 2
- 241001403027 unclassified Carnobacterium Species 0.000 description 2
- 241001099133 unclassified Paenibacillus Species 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- VFFNZZXXTGXBOG-LURJTMIESA-N (+)-a(S)-butyr-amido-r-butyrolactone Chemical compound CCCC(=O)N[C@H]1CCOC1=O VFFNZZXXTGXBOG-LURJTMIESA-N 0.000 description 1
- SFWLDKQAUHFCBS-AOEYGKNYSA-N (1S,4S,13S,16S,19S,22S,25S,28R,31S,37S,40S,41S,44R,47S,50S,53S,56R,65S,70S)-44-amino-47-(4-aminobutyl)-4,16,22-tribenzyl-31-[(R)-carboxy(hydroxy)methyl]-2,5,14,17,20,23,26,29,32,35,38,45,48,51,54,57,67-heptadecahydroxy-37-(2-hydroxy-2-iminoethyl)-50-(3-hydroxy-3-iminopropyl)-41,70-dimethyl-8-oxo-25-propan-2-yl-42,69,72-trithia-3,6,9,15,18,21,24,27,30,33,36,39,46,49,52,55,58,60,66-nonadecazapentacyclo[38.18.9.319,56.328,53.09,13]triheptaconta-2,5,14,17,20,23,26,29,32,35,38,45,48,51,54,57,66-heptadecaene-65-carboxylic acid Chemical compound CC(C)[C@@H]1\N=C(O)/[C@H](Cc2ccccc2)\N=C(O)/[C@@H]2\N=C(O)/[C@H](Cc3ccccc3)\N=C(O)/[C@@H]3CCCN3C(=O)C\N=C(O)/[C@H](Cc3ccccc3)\N=C(O)/[C@@H]3CNCCCC[C@H](\N=C(O)\[C@@H]4\N=C(O)\[C@H](CC(O)=N)\N=C(O)\C\N=C(O)/[C@@H](\N=C(O)\[C@H](CSC[C@@H](N=C(O)[C@H](CCC(O)=N)N=C(O)[C@H](CCCCN)N=C(O)[C@@H](N)CS[C@H]4C)C(O)=N[C@@H](CS[C@H]2C)C(O)=N3)\N=C1\O)[C@@H](O)C(O)=O)C(O)=O SFWLDKQAUHFCBS-AOEYGKNYSA-N 0.000 description 1
- VJNFPXDPZJZUKS-DSJRILELSA-N (2e,4e,6e,8e)-n-[(3s,6s,9s,12s,15s,16r)-6,9-bis(2-amino-2-oxoethyl)-3-[(2r)-butan-2-yl]-16-methyl-2,5,8,11,14-pentaoxo-12-propan-2-yl-1-oxa-4,7,10,13-tetrazacyclohexadec-15-yl]-9-(3-bromo-4-hydroxyphenyl)nona-2,4,6,8-tetraenamide Chemical compound C[C@H]1OC(=O)[C@H]([C@H](C)CC)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H]1NC(=O)\C=C\C=C\C=C\C=C\C1=CC=C(O)C(Br)=C1 VJNFPXDPZJZUKS-DSJRILELSA-N 0.000 description 1
- BEJKOYIMCGMNRB-GRHHLOCNSA-N (2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 BEJKOYIMCGMNRB-GRHHLOCNSA-N 0.000 description 1
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 1
- 108010056311 A-FF22 Proteins 0.000 description 1
- 241000047203 Acaryochloris marina MBIC11017 Species 0.000 description 1
- 241000589220 Acetobacter Species 0.000 description 1
- 241000186425 Acidipropionibacterium jensenii Species 0.000 description 1
- 241000186335 Acidipropionibacterium thoenii Species 0.000 description 1
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 1
- 241000983982 Actinoplanes liguriensis Species 0.000 description 1
- 241000222518 Agaricus Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 241000223600 Alternaria Species 0.000 description 1
- 241000186063 Arthrobacter Species 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000228215 Aspergillus aculeatus Species 0.000 description 1
- 241001513093 Aspergillus awamori Species 0.000 description 1
- 241000892910 Aspergillus foetidus Species 0.000 description 1
- 241001225321 Aspergillus fumigatus Species 0.000 description 1
- 241001480052 Aspergillus japonicus Species 0.000 description 1
- 241000351920 Aspergillus nidulans Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000223651 Aureobasidium Species 0.000 description 1
- 241000193749 Bacillus coagulans Species 0.000 description 1
- 241000006382 Bacillus halodurans Species 0.000 description 1
- 101001138049 Bacillus licheniformis Lantibiotic lichenicidin VK21 A2 Proteins 0.000 description 1
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 1
- 101000959010 Bacillus subtilis (strain 168) Putative ABC transporter ATP-binding protein AlbC Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 244000177578 Bacterium linens Species 0.000 description 1
- 235000012539 Bacterium linens Nutrition 0.000 description 1
- 241001536303 Botryococcus braunii Species 0.000 description 1
- 241000190146 Botryosphaeria Species 0.000 description 1
- 241000458359 Brevibacillus sp. Species 0.000 description 1
- 241000186146 Brevibacterium Species 0.000 description 1
- 241000206603 Brochothrix campestris Species 0.000 description 1
- JSWKNDSDVHJUKY-MNVIWFPGSA-N CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC(=O)[C@@H]3CS[C@@H](C)[C@@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H]4NC(=O)[C@@H]([NH3+])CS[C@H]4C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)NC([C@H](C)S\C=C/NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC([O-])=O)C(=O)N2 Chemical compound CC[C@@H](C)[C@@H]1NC(=O)[C@@H]2CS[C@@H](C)[C@@H](NC(=O)[C@@H]3CS[C@@H](C)[C@@H](NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@@H]4NC(=O)[C@@H]([NH3+])CS[C@H]4C)C(=O)N[C@@H](CC(C)C)C(=O)N4CCC[C@H]4C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N3)C(=O)N[C@@H](CC(C)C)C(=O)NC([C@H](C)S\C=C/NC1=O)C(=O)NC(=C)C(=O)N[C@@H](CCC([O-])=O)C(=O)N2 JSWKNDSDVHJUKY-MNVIWFPGSA-N 0.000 description 1
- 101100436077 Caenorhabditis elegans asm-1 gene Proteins 0.000 description 1
- 108700020694 Carnobacterium divergens dvnA Proteins 0.000 description 1
- 101000715434 Carnobacterium maltaromaticum Bacteriocin carnobacteriocin B2 Proteins 0.000 description 1
- 241000229225 Carnobacterium sp. Species 0.000 description 1
- 101710107553 Carnocyclin-A Proteins 0.000 description 1
- 241000146399 Ceriporiopsis Species 0.000 description 1
- 241000259840 Chaetomidium Species 0.000 description 1
- 241001057137 Chaetomium fimeti Species 0.000 description 1
- 241000195649 Chlorella <Chlorellales> Species 0.000 description 1
- 241000985909 Chrysosporium keratinophilum Species 0.000 description 1
- 241001674013 Chrysosporium lucknowense Species 0.000 description 1
- 241001556045 Chrysosporium merdarium Species 0.000 description 1
- 241000080524 Chrysosporium queenslandicum Species 0.000 description 1
- 241001674001 Chrysosporium tropicum Species 0.000 description 1
- 241000722206 Chrysotila carterae Species 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001136168 Clavibacter michiganensis Species 0.000 description 1
- 241000221760 Claviceps Species 0.000 description 1
- 108010090591 Cloacin Proteins 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 108700008404 Clostridium botulinum btcB Proteins 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193452 Clostridium tyrobutyricum Species 0.000 description 1
- 241000228437 Cochliobolus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 241000907165 Coleofasciculus chthonoplastes Species 0.000 description 1
- 101710180984 Colicin-10 Proteins 0.000 description 1
- 101710182016 Colicin-D Proteins 0.000 description 1
- 101710164069 Colicin-E1* Proteins 0.000 description 1
- 101710159063 Colicin-E6 Proteins 0.000 description 1
- 101710159064 Colicin-E7 Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 241001085790 Coprinopsis Species 0.000 description 1
- 241001509964 Coptotermes Species 0.000 description 1
- 241001252397 Corynascus Species 0.000 description 1
- 241000221755 Cryphonectria Species 0.000 description 1
- 241001337994 Cryptococcus <scale insect> Species 0.000 description 1
- 241000223211 Curvularia lunata Species 0.000 description 1
- 241000371644 Curvularia ravenelii Species 0.000 description 1
- 241000159509 Cyanothece sp. ATCC 51142 Species 0.000 description 1
- 241000920998 Cyanothece sp. PCC 7424 Species 0.000 description 1
- 241000132165 Cyanothece sp. PCC 8801 Species 0.000 description 1
- 241000235646 Cyberlindnera jadinii Species 0.000 description 1
- 101100166522 Dictyostelium discoideum cycB gene Proteins 0.000 description 1
- 241000935926 Diplodia Species 0.000 description 1
- 241000195632 Dunaliella tertiolecta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241001468179 Enterococcus avium Species 0.000 description 1
- 108700031577 Enterococcus bacA Proteins 0.000 description 1
- 241000194028 Enterococcus columbae Species 0.000 description 1
- 101000898108 Enterococcus sp Enterocin E-760 Proteins 0.000 description 1
- 101000998566 Escherichia coli Colicin-E2 immunity protein Proteins 0.000 description 1
- 101000998560 Escherichia coli Colicin-E5 immunity protein Proteins 0.000 description 1
- 101000599531 Escherichia coli Colicin-E5 immunity protein in ColE9 Proteins 0.000 description 1
- 101000998558 Escherichia coli Colicin-E6 immunity protein Proteins 0.000 description 1
- 101000998556 Escherichia coli Colicin-E7 immunity protein Proteins 0.000 description 1
- 101000998554 Escherichia coli Colicin-E8 immunity protein Proteins 0.000 description 1
- 101000599537 Escherichia coli Colicin-E8 immunity protein in ColE6 Proteins 0.000 description 1
- 101000998552 Escherichia coli Colicin-E9 immunity protein Proteins 0.000 description 1
- 101001056192 Escherichia coli Microcin-J25 export ATP-binding/permease protein McjD Proteins 0.000 description 1
- 241000206602 Eukaryota Species 0.000 description 1
- 241000221433 Exidia Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000145614 Fusarium bactridioides Species 0.000 description 1
- 241000223194 Fusarium culmorum Species 0.000 description 1
- 241000223195 Fusarium graminearum Species 0.000 description 1
- 241000223221 Fusarium oxysporum Species 0.000 description 1
- 241001112697 Fusarium reticulatum Species 0.000 description 1
- 241001014439 Fusarium sarcochroum Species 0.000 description 1
- 241000223192 Fusarium sporotrichioides Species 0.000 description 1
- 241001465753 Fusarium torulosum Species 0.000 description 1
- 108010085026 GE 2270 A Proteins 0.000 description 1
- 108010008945 General Transcription Factors Proteins 0.000 description 1
- 102000006580 General Transcription Factors Human genes 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 241000193419 Geobacillus kaustophilus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100024977 Glutamine-tRNA ligase Human genes 0.000 description 1
- 241000206581 Gracilaria Species 0.000 description 1
- 241000204942 Halobacterium sp. Species 0.000 description 1
- 101800003289 Halocin-C8 Proteins 0.000 description 1
- 101710186478 Hiracin-JM79 immunity factor Proteins 0.000 description 1
- 241001497663 Holomastigotoides Species 0.000 description 1
- 241000223198 Humicola Species 0.000 description 1
- 241000223199 Humicola grisea Species 0.000 description 1
- 241001480714 Humicola insolens Species 0.000 description 1
- 241000222342 Irpex Species 0.000 description 1
- 241000222344 Irpex lacteus Species 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000191953 Kocuria varians Species 0.000 description 1
- 241000235058 Komagataella pastoris Species 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 125000000393 L-methionino group Chemical group [H]OC(=O)[C@@]([H])(N([H])[*])C([H])([H])C(SC([H])([H])[H])([H])[H] 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000186713 Lactobacillus amylovorus Species 0.000 description 1
- 101000757183 Lactobacillus amylovorus Bacteriocin amylovorin-L Proteins 0.000 description 1
- 101100074186 Lactobacillus johnsonii (strain CNCM I-12250 / La1 / NCC 533) lafX gene Proteins 0.000 description 1
- 241000186605 Lactobacillus paracasei Species 0.000 description 1
- 241000186782 Lactobacillus sakei L45 Species 0.000 description 1
- 241000167365 Lactobacillus salivarius cp400 Species 0.000 description 1
- 241000178948 Lactococcus sp. Species 0.000 description 1
- 101000693526 Latilactobacillus sakei Bacteriocin sakacin-P Proteins 0.000 description 1
- 241000222435 Lentinula Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 241000192003 Leuconostoc carnosum Species 0.000 description 1
- 229920002097 Lichenin Polymers 0.000 description 1
- 241000186805 Listeria innocua Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241001344133 Magnaporthe Species 0.000 description 1
- 241000183011 Melanocarpus Species 0.000 description 1
- 241001184659 Melanocarpus albomyces Species 0.000 description 1
- 108090000301 Membrane transport proteins Proteins 0.000 description 1
- 102000003939 Membrane transport proteins Human genes 0.000 description 1
- 241000123315 Meripilus Species 0.000 description 1
- 241000906785 Microbispora sp. Species 0.000 description 1
- 101710175599 Microcin N Proteins 0.000 description 1
- MQGFYNRGFWXAKA-GXSYYHJRSA-N Micrococcin Chemical compound C[C@H](O)CNC(=O)C(=C/C)/NC(=O)C1=CSC(C=2N=C(SC=2)C=2N=C3C=4N=C(SC=4)[C@H]([C@@H](C)O)NC(=O)C=4N=C(SC=4)[C@@H](C(C)C)NC(=O)C=4N=C(SC=4)C(=C/C)/NC(=O)[C@H]([C@@H](C)O)NC(=O)C=4N=C(SC=4)C3=CC=2)=N1 MQGFYNRGFWXAKA-GXSYYHJRSA-N 0.000 description 1
- XLMXLFRJEYNHMO-JMMJCSMWSA-N Micrococcin P2 Natural products CC=C(NC(=O)c1csc(n1)c2csc(n2)c3ccc4c5nc(cs5)C(=O)N[C@@H]([C@@H](C)O)C(=O)NC(=CC)c6nc(cs6)C(=O)N[C@@H](C(C)C)c7nc(cs7)C(=O)N[C@@H]([C@@H](C)O)c8nc(cs8)c4n3)C(=O)NCC(=O)C XLMXLFRJEYNHMO-JMMJCSMWSA-N 0.000 description 1
- 241000192041 Micrococcus Species 0.000 description 1
- 241000235395 Mucor Species 0.000 description 1
- 241000226677 Myceliophthora Species 0.000 description 1
- 241000863423 Myxococcus fulvus Species 0.000 description 1
- 241000221960 Neurospora Species 0.000 description 1
- 241000221961 Neurospora crassa Species 0.000 description 1
- 101100204282 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) Asm-1 gene Proteins 0.000 description 1
- 241001268000 Nodularia spumigena CCY9414 Species 0.000 description 1
- 101100488513 Nostoc sp. (strain PCC 7120 / SAG 25.82 / UTEX 2576) asr1611 gene Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 1
- 241000223785 Paramecium Species 0.000 description 1
- ZGJIVWQOEHQWLW-SWTUTNCKSA-N Patellamide A Chemical compound C([C@H](N=1)C(=O)N[C@@H](C=2SC=C(N=2)C(=O)N[C@H](C2=N[C@@H]([C@H](O2)C)C(=O)N[C@@H]2C(C)C)[C@@H](C)CC)C(C)C)OC=1[C@H]([C@@H](C)CC)NC(=O)C1=CSC2=N1 ZGJIVWQOEHQWLW-SWTUTNCKSA-N 0.000 description 1
- 101000574469 Pediococcus acidilactici Bacteriocin pediocin PA-1 Proteins 0.000 description 1
- 241000191996 Pediococcus pentosaceus Species 0.000 description 1
- 108010056995 Perforin Proteins 0.000 description 1
- 102000004503 Perforin Human genes 0.000 description 1
- 241000222385 Phanerochaete Species 0.000 description 1
- 241000222393 Phanerochaete chrysosporium Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 241000235379 Piromyces Species 0.000 description 1
- 241001451060 Poitrasia Species 0.000 description 1
- AEKNYBWUEYNWMJ-QWOOXDRHSA-N Pramiconazole Chemical compound O=C1N(C(C)C)CCN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(CO3)C=3C(=CC(F)=CC=3)F)=CC=2)C=C1 AEKNYBWUEYNWMJ-QWOOXDRHSA-N 0.000 description 1
- 241000192137 Prochlorococcus marinus Species 0.000 description 1
- 241000186428 Propionibacterium freudenreichii Species 0.000 description 1
- 101710095304 Propionicin-F Proteins 0.000 description 1
- 101710081454 Protein AlbB Proteins 0.000 description 1
- 101100524675 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) rhlI gene Proteins 0.000 description 1
- 241000589614 Pseudomonas stutzeri Species 0.000 description 1
- 241000383860 Pseudoplectania Species 0.000 description 1
- 241001497658 Pseudotrichonympha Species 0.000 description 1
- 101710189515 Putative ABC transporter ATP-binding protein AlbC Proteins 0.000 description 1
- 101710100336 Pyocin-S2 Proteins 0.000 description 1
- 108010025955 Pyocins Proteins 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 241000589194 Rhizobium leguminosarum Species 0.000 description 1
- 241000589193 Rhizobium leguminosarum bv. trifolii Species 0.000 description 1
- 241000235402 Rhizomucor Species 0.000 description 1
- 241000235403 Rhizomucor miehei Species 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241000235072 Saccharomyces bayanus Species 0.000 description 1
- 101100439280 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CLB1 gene Proteins 0.000 description 1
- ACQJWVPNGVNRCD-UHFFFAOYSA-N Sakacin A Chemical class CC(C)(C)N(C)C(=O)NC(C)NC(=O)C(N)CC(O)=O ACQJWVPNGVNRCD-UHFFFAOYSA-N 0.000 description 1
- VMETVXNVLXCEFC-UHFFFAOYSA-N Sakacin P Chemical class NC(=O)C(=O)C(C)NC(=O)OC(C)(C)C VMETVXNVLXCEFC-UHFFFAOYSA-N 0.000 description 1
- 101710088431 Sakacin-A immunity factor Proteins 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 241000222480 Schizophyllum Species 0.000 description 1
- 241000235347 Schizosaccharomyces pombe Species 0.000 description 1
- 241000223255 Scytalidium Species 0.000 description 1
- 241001622809 Serratia plymuthica Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 241000192085 Staphylococcus gallinarum Species 0.000 description 1
- 241000192086 Staphylococcus warneri Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000264435 Streptococcus dysgalactiae subsp. equisimilis Species 0.000 description 1
- 241000194048 Streptococcus equi Species 0.000 description 1
- 101001138042 Streptococcus mutans Lantibiotic mutacin-1140 Proteins 0.000 description 1
- 241001147849 Streptomyces griseoluteus Species 0.000 description 1
- 101000968300 Streptomyces griseoverticillatus Lantibiotic duramycin Proteins 0.000 description 1
- 101710089855 Subtilosin-A Proteins 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 102220602178 Synaptotagmin-3_L50A_mutation Human genes 0.000 description 1
- 241000306507 Synechococcus sp. PCC 7335 Species 0.000 description 1
- 241000228341 Talaromyces Species 0.000 description 1
- 241001215623 Talaromyces cellulolyticus Species 0.000 description 1
- 241001136494 Talaromyces funiculosus Species 0.000 description 1
- 241001540751 Talaromyces ruber Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 241000228178 Thermoascus Species 0.000 description 1
- 241000223258 Thermomyces lanuginosus Species 0.000 description 1
- 241001313536 Thermothelomyces thermophila Species 0.000 description 1
- 241000589500 Thermus aquaticus Species 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 241000183057 Thielavia microspora Species 0.000 description 1
- 241000182980 Thielavia ovispora Species 0.000 description 1
- 241000183053 Thielavia subthermophila Species 0.000 description 1
- 241001495429 Thielavia terrestris Species 0.000 description 1
- UJNDUGQLLYFVMS-UHFFFAOYSA-N Thiocillin II Natural products N1=C2C(N=3)=CSC=3C(C(C)OC)NC(=O)C(N=3)=CSC=3C(C(C)(C)O)NC(=O)C(N=3)=CSC=3C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=3)=CSC=3C2=CC=C1C(SC=1)=NC=1C1=NC(C(=O)NC(=CC)C(=O)NCC(C)O)=CS1 UJNDUGQLLYFVMS-UHFFFAOYSA-N 0.000 description 1
- NSFFHOGKXHRQEW-UHFFFAOYSA-N Thiostrepton B Natural products N1C(=O)C(C)NC(=O)C(=C)NC(=O)C(C)NC(=O)C(C(C)CC)NC(C(C2=N3)O)C=CC2=C(C(C)O)C=C3C(=O)OC(C)C(C=2SC=C(N=2)C2N=3)NC(=O)C(N=4)=CSC=4C(C(C)(O)C(C)O)NC(=O)C(N=4)CSC=4C(=CC)NC(=O)C(C(C)O)NC(=O)C(N=4)=CSC=4C21CCC=3C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000002262 Thromboplastin Human genes 0.000 description 1
- 108010000499 Thromboplastin Proteins 0.000 description 1
- 241001149964 Tolypocladium Species 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 241000223259 Trichoderma Species 0.000 description 1
- 241000223260 Trichoderma harzianum Species 0.000 description 1
- 241000378866 Trichoderma koningii Species 0.000 description 1
- 241000223262 Trichoderma longibrachiatum Species 0.000 description 1
- 241000499912 Trichoderma reesei Species 0.000 description 1
- 241000223261 Trichoderma viride Species 0.000 description 1
- 241000215642 Trichophaea Species 0.000 description 1
- 101100544333 Trichormus variabilis (strain ATCC 29413 / PCC 7937) Ava_4222 gene Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000082085 Verticillium <Phyllachorales> Species 0.000 description 1
- 241001507667 Volvariella Species 0.000 description 1
- 241000409279 Xerochrysium dermatitidis Species 0.000 description 1
- 241001523965 Xylaria Species 0.000 description 1
- 241001464867 [Ruminococcus] gnavus Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108010030369 acidocin 8912 Proteins 0.000 description 1
- 108010085690 acidocin J1132 Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 108091006088 activator proteins Proteins 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 108010047169 amylovorin L471 Proteins 0.000 description 1
- TWBVBKLXMJGRPJ-UHFFFAOYSA-N anacyclamide a10 Chemical compound N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C2CCCN2C(=O)C(CO)NC(=O)CNC(=O)C1CC1=CNC2=CC=CC=C12 TWBVBKLXMJGRPJ-UHFFFAOYSA-N 0.000 description 1
- 108010055869 ancovenin Proteins 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000000656 anti-yeast Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 229940091771 aspergillus fumigatus Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 108010060043 bacteriocin J46 Proteins 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 238000002869 basic local alignment search tool Methods 0.000 description 1
- 108010060301 bavaricin A Proteins 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 108700031626 bottromycin A(2) Proteins 0.000 description 1
- KSIZLOPUXFSFNR-UHFFFAOYSA-N bottromycin A2 Natural products N=1C=CSC=1C(CC(=O)OC)NC(=O)C(NC(=O)C(NC=1C(NC(=O)C(C(C)C)NC(=O)C2C(C)CCN2C(=O)CN=1)C(C)(C)C)C(C)(C)C)C(C)C1=CC=CC=C1 KSIZLOPUXFSFNR-UHFFFAOYSA-N 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 108010016178 carnocin UI49 Proteins 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- FFLJEMWVYVKPDW-UMNFMQIXSA-N chembl263049 Chemical compound O([C@H]1[C@H]2OCC3=C(N(C=4C=CC=C(C3=4)COC1=O)O)C(=O)OC[C@H]1C=3SC=C(N=3)C3=NC(=C(O)C=C3C=3SC=C(N=3)C(=O)N[C@H](C(=O)N/C(C=3SC=C(N=3)C(=O)N[C@@H]2C=2SC=C(N=2)C(=O)N1)=C(C)/OC)[C@@H](C)O)C=1SC=C(N=1)C(=O)NC(=C)C(N)=O)[C@H]1C[C@](C)(O)[C@H](N(C)C)[C@H](C)O1 FFLJEMWVYVKPDW-UMNFMQIXSA-N 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 108010063293 cinnamycin Proteins 0.000 description 1
- QJDWKBINWOWJNZ-OURZNGJWSA-N cinnamycin Chemical compound CC(C)[C@@H]1NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@@H]2NC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CCCN3C(=O)CNC(=O)[C@H](Cc3ccccc3)NC(=O)[C@@H]3CNCCCC[C@H](NC(=O)[C@@H]4NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CSC[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CS[C@H]4C)C(=O)N[C@@H](CS[C@H]2C)C(=O)N3)NC1=O)[C@@H](O)C(O)=O)C(O)=O QJDWKBINWOWJNZ-OURZNGJWSA-N 0.000 description 1
- 108010071321 circularin A Proteins 0.000 description 1
- LOHQECMUTAPWAC-UHFFFAOYSA-N coagulin Natural products C1C(C)=C(CO)C(=O)OC1C1(C)C(C2(C)CCC3C4(C(=O)CC=CC4=CCC43)C)(O)CCC24O1 LOHQECMUTAPWAC-UHFFFAOYSA-N 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 108010052059 curvaticin FS47 Proteins 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002999 depolarising effect Effects 0.000 description 1
- 230000009025 developmental regulation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 108010005174 divercin V41 Proteins 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 108010067071 duramycin Proteins 0.000 description 1
- 108010025837 duramycin B Proteins 0.000 description 1
- 108010025839 duramycin C Proteins 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 108010049056 enterocin A Proteins 0.000 description 1
- 108010049051 enterocin B Proteins 0.000 description 1
- 108010004819 enterocin CRL35 Chemical group 0.000 description 1
- 108010047973 enterocin P Proteins 0.000 description 1
- 108010047736 enterocin Q Proteins 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 108010079222 epicidin 280 Proteins 0.000 description 1
- 108010064962 epidermin Proteins 0.000 description 1
- 108010044807 epilancin K7 Proteins 0.000 description 1
- 238000006345 epimerization reaction Methods 0.000 description 1
- 108010037391 fulvocin C Proteins 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108010047651 gallidermin Proteins 0.000 description 1
- 108010020998 gassericin A Proteins 0.000 description 1
- 108010020991 gassericin T Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 108010051239 glutaminyl-tRNA synthetase Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 101150107068 gsiB gene Proteins 0.000 description 1
- 241000946447 haloarchaeon S8a Species 0.000 description 1
- 108010051540 halocin S8 Proteins 0.000 description 1
- 108010059016 helveticin J Proteins 0.000 description 1
- 108010083434 hiracin JM79 Proteins 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 101150099805 htpG gene Proteins 0.000 description 1
- 230000033444 hydroxylation Effects 0.000 description 1
- 238000005805 hydroxylation reaction Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 101150109249 lacI gene Proteins 0.000 description 1
- 101150066555 lacZ gene Proteins 0.000 description 1
- 108010087689 lacticin 481 Proteins 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940054346 lactobacillus helveticus Drugs 0.000 description 1
- 108010062224 lactocin S Proteins 0.000 description 1
- 108010074479 lactococcin 972 Proteins 0.000 description 1
- 101150012019 lafA gene Proteins 0.000 description 1
- 108010037248 lantibiotic Pep5 Proteins 0.000 description 1
- 108010075087 laterosporulin Proteins 0.000 description 1
- 108010084630 leucocin A-UAL 187 Proteins 0.000 description 1
- 108010065723 leucocin B-Ta11a Proteins 0.000 description 1
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 1
- 108010047534 linocin Proteins 0.000 description 1
- 238000005710 macrocyclization reaction Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- DWPCPZJAHOETAG-UHFFFAOYSA-N meso-lanthionine Natural products OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- KSIZLOPUXFSFNR-XZNJZDOZSA-N methyl (3r)-3-[[(2s,3s)-2-[[(2s)-2-[[(6s,9s,12s,13r)-6-tert-butyl-13-methyl-2,8,11-trioxo-9-propan-2-yl-1,4,7,10-tetrazabicyclo[10.3.0]pentadec-4-en-5-yl]amino]-3,3-dimethylbutanoyl]amino]-3-phenylbutanoyl]amino]-3-(1,3-thiazol-2-yl)propanoate Chemical compound C1([C@H](C)[C@H](NC(=O)[C@@H](\N=C/2[C@@H](NC(=O)[C@H](C(C)C)NC(=O)[C@@H]3[C@H](C)CCN3C(=O)CN\2)C(C)(C)C)C(C)(C)C)C(=O)N[C@H](CC(=O)OC)C=2SC=CN=2)=CC=CC=C1 KSIZLOPUXFSFNR-XZNJZDOZSA-N 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- DPWKTZRJGMZNFS-IGRUFWJISA-N microcin B17 Chemical compound CC(C)[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](CS)C(=O)NCC(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)CC1=CNC=N1 DPWKTZRJGMZNFS-IGRUFWJISA-N 0.000 description 1
- 108010009882 micrococcin Proteins 0.000 description 1
- MQGFYNRGFWXAKA-TWSKATCCSA-N micrococcin P1 Natural products CC=C(NC(=O)c1csc(n1)c2csc(n2)c3ccc4c5nc(cs5)C(=O)N[C@@H]([C@@H](C)O)C(=O)NC(=CC)c6nc(cs6)C(=O)N[C@@H](C(C)C)c7nc(cs7)C(=O)N[C@@H]([C@@H](C)O)c8nc(cs8)c4n3)C(=O)NC[C@@H](C)O MQGFYNRGFWXAKA-TWSKATCCSA-N 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- SUJOIPVTNUVDCB-UHFFFAOYSA-N mutactin Natural products CC1=CC(O)=C2C(=O)CC(O)CC2=C1C1=CC(O)=CC(=O)O1 SUJOIPVTNUVDCB-UHFFFAOYSA-N 0.000 description 1
- FFLJEMWVYVKPDW-VCUUIXPJSA-N nocathiacin I Natural products COC(=C1NC(=O)[C@@H](NC(=O)c2csc(n2)c3cc(O)c(nc3c4csc(n4)[C@@H]5COC(=O)c6c7CO[C@@H]([C@H](NC(=O)c8csc1n8)c9nc(cs9)C(=O)N5)[C@H](O[C@H]%10C[C@](C)(O)[C@@H]([C@H](C)O%10)N(C)C)C(=O)OCc%11cccc(c7%11)n6O)c%12nc(cs%12)C(=O)NC(=C)C(=O)N)[C@@H](C)O)C FFLJEMWVYVKPDW-VCUUIXPJSA-N 0.000 description 1
- 108010081596 nocathiacin I Proteins 0.000 description 1
- 108010079179 nukacin ISK-1 Proteins 0.000 description 1
- 101150093139 ompT gene Proteins 0.000 description 1
- 108010032824 paenicidin A Proteins 0.000 description 1
- 108010057193 patellamide A Proteins 0.000 description 1
- TXYYEFNIVWFRLF-UHFFFAOYSA-N patellamide A Natural products N=1C2=CSC=1C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C(N=1)COC=1C(N=1)=CSC=1C(C(C)C)NC(=O)C(C(C)CC)NC(=O)C1C(C)OC2=N1 TXYYEFNIVWFRLF-UHFFFAOYSA-N 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- FLTWKHKMXZLDNR-CVMNUACMSA-N pediocin ach Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)NCC(=O)N[C@@H](CC1N=CN=C1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)OC(=O)[C@H](CS)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1N=CN=C1)[C@@H](C)CC)[C@@H](C)O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](N)CCCCN)C(C)C)[C@@H](C)O)C1C=NC=N1 FLTWKHKMXZLDNR-CVMNUACMSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 108010035592 piscicolin 126 Proteins 0.000 description 1
- 108010080433 planosporicin Proteins 0.000 description 1
- 108010046985 plantaricin 1.25 Proteins 0.000 description 1
- 108010011394 plantaricin 423 Proteins 0.000 description 1
- 108010010613 plantaricin A Proteins 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 1
- 125000001844 prenyl group Chemical group [H]C([*])([H])C([H])=C(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108010070837 propionicin T1 Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000008964 regulation of RNA stability Effects 0.000 description 1
- 238000005067 remediation Methods 0.000 description 1
- 230000000754 repressing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010036148 ruminococcin A Proteins 0.000 description 1
- 229960002181 saccharomyces boulardii Drugs 0.000 description 1
- 108010027327 sakacin A Proteins 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 108010043542 streptin Proteins 0.000 description 1
- 229940115920 streptococcus dysgalactiae Drugs 0.000 description 1
- 229940115921 streptococcus equinus Drugs 0.000 description 1
- 108010082567 subtilin Proteins 0.000 description 1
- 101150024821 tetO gene Proteins 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 108700020534 tetracycline resistance-encoding transposon repressor Proteins 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 108010051977 thermophilin 13 Proteins 0.000 description 1
- 108010057451 thiocillin Proteins 0.000 description 1
- 229930188234 thiocillin Natural products 0.000 description 1
- FEORQDDAQBRWPT-FANUFGRASA-N thiocillin I Natural products CC=C(NC(=O)c1csc(n1)c2csc(n2)c3ccc4c5nc(cs5)C(=O)N[C@@H]([C@@H](C)O)C(=O)NC(=CC)c6nc(cs6)C(=O)N[C@H](c7nc(cs7)C(=O)N[C@@H]([C@@H](C)O)c8nc(cs8)c4n3)C(C)(C)O)C(=O)NC[C@@H](C)O FEORQDDAQBRWPT-FANUFGRASA-N 0.000 description 1
- UJNDUGQLLYFVMS-MXAYCALOSA-N thiocillin II Natural products CO[C@H](C)[C@@H]1NC(=O)c2csc(n2)[C@@H](NC(=O)c3csc(n3)C(=CC)NC(=O)[C@@H](NC(=O)c4csc(n4)c5ccc(nc5c6csc1n6)c7nc(cs7)c8nc(cs8)C(=O)NC(=CC)C(=O)NC[C@@H](C)O)[C@@H](C)O)C(C)(C)O UJNDUGQLLYFVMS-MXAYCALOSA-N 0.000 description 1
- XNGPWJFNCGGKBM-DUYCCGHJSA-N thiocillin III Natural products CO[C@H](C)[C@@H]1NC(=O)c2csc(n2)[C@@H](NC(=O)c3csc(n3)C(=CC)NC(=O)[C@@H](NC(=O)c4csc(n4)c5ccc(nc5c6csc1n6)c7nc(cs7)c8nc(cs8)C(=O)NC(=CC)C(=O)NC[C@@H](C)O)[C@@H](C)O)C(C)C XNGPWJFNCGGKBM-DUYCCGHJSA-N 0.000 description 1
- VQHCTFJXSIUDOJ-CPTXHEQMSA-N thiocillin IV Natural products CO[C@H](C)[C@@H]1NC(=O)c2csc(n2)[C@@H](NC(=O)c3csc(n3)C(=CC)NC(=O)[C@@H](NC(=O)c4csc(n4)c5ccc(nc5c6csc1n6)c7nc(cs7)c8nc(cs8)C(=O)NC(=CC)C(=O)NCC(=O)C)[C@@H](C)O)C(C)C VQHCTFJXSIUDOJ-CPTXHEQMSA-N 0.000 description 1
- FEORQDDAQBRWPT-NBBXXHIDSA-N thiocillin i Chemical compound CC(O)CNC(=O)C(=C/C)\NC(=O)C1=CSC(C=2N=C(SC=2)C=2N=C3C=4N=C(SC=4)C(C(C)O)NC(=O)C=4N=C(SC=4)C(NC(=O)C=4N=C(SC=4)C(=C\C)/NC(=O)C(C(C)O)NC(=O)C=4N=C(SC=4)C3=CC=2)C(C)(C)O)=N1 FEORQDDAQBRWPT-NBBXXHIDSA-N 0.000 description 1
- UJNDUGQLLYFVMS-HGELYGIESA-N thiocillin ii Chemical compound N1=C2C(N=3)=CSC=3C(C(C)OC)NC(=O)C(N=3)=CSC=3C(C(C)(C)O)NC(=O)C(N=3)=CSC=3\C(=C/C)NC(=O)C(C(C)O)NC(=O)C(N=3)=CSC=3C2=CC=C1C(SC=1)=NC=1C1=NC(C(=O)N\C(=C\C)C(=O)NCC(C)O)=CS1 UJNDUGQLLYFVMS-HGELYGIESA-N 0.000 description 1
- NSFFHOGKXHRQEW-AIHSUZKVSA-N thiostrepton Chemical compound C([C@]12C=3SC=C(N=3)C(=O)N[C@H](C(=O)NC(/C=3SC[C@@H](N=3)C(=O)N[C@H](C=3SC=C(N=3)C(=O)N[C@H](C=3SC=C(N=3)[C@H]1N=1)[C@@H](C)OC(=O)C3=CC(=C4C=C[C@H]([C@@H](C4=N3)O)N[C@H](C(N[C@@H](C)C(=O)NC(=C)C(=O)N[C@@H](C)C(=O)N2)=O)[C@@H](C)CC)[C@H](C)O)[C@](C)(O)[C@@H](C)O)=C\C)[C@@H](C)O)CC=1C1=NC(C(=O)NC(=C)C(=O)NC(=C)C(N)=O)=CS1 NSFFHOGKXHRQEW-AIHSUZKVSA-N 0.000 description 1
- 229930188070 thiostrepton Natural products 0.000 description 1
- 229940063214 thiostrepton Drugs 0.000 description 1
- NSFFHOGKXHRQEW-OFMUQYBVSA-N thiostrepton A Natural products CC[C@H](C)[C@@H]1N[C@@H]2C=Cc3c(cc(nc3[C@H]2O)C(=O)O[C@H](C)[C@@H]4NC(=O)c5csc(n5)[C@@H](NC(=O)[C@H]6CSC(=N6)C(=CC)NC(=O)[C@@H](NC(=O)c7csc(n7)[C@]8(CCC(=N[C@@H]8c9csc4n9)c%10nc(cs%10)C(=O)NC(=C)C(=O)NC(=C)C(=O)N)NC(=O)[C@H](C)NC(=O)C(=C)NC(=O)[C@H](C)NC1=O)[C@@H](C)O)[C@](C)(O)[C@@H](C)O)[C@H](C)O NSFFHOGKXHRQEW-OFMUQYBVSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001483843 unclassified Pseudomonas Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108010005406 variacin Proteins 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/101—Plasmid DNA for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/20—Pseudochromosomes, minichrosomosomes
- C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
Definitions
- Embodiments herein relate to a method for producing a product of interest with a microbial host using an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to the host, optionally wherein the genetic activity of said first nucleic acid molecule is controlled.
- Antibiotics are widely used as selection agents for the production of a product of interest in microbial cells.
- antibiotics such as large-scale spreading of antibiotics in the environment.
- sequence coding for the resistance of the antibiotic in the DNA constructs represent an energetic burden for the cell and therefore negatively affects the yield of the product. This energetic burden is particularly relevant when the resistance-conferring gene is a large gene, when it is expressed at a high level and/or when it is expressed constitutively.
- a method for producing a product of interest with a microbial host comprising the steps of:
- Step a) comprises providing a microbial host comprising an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to the host, optionally wherein the genetic activity of said first nucleic acid sequence is controlled.
- the auto-replicative extra-chromosomal nucleic acid molecule can be provided in a microbial host (e.g., a microbial cell as described herein).
- the host or a predecessor of the host may have been previously transformed with the auto-replicative extra-chromosomal nucleic acid molecule.
- step a) comprises providing a microbial cell host comprising an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to the host, optionally wherein the genetic activity of said first nucleic acid sequence is controlled.
- the microbial host is transformed with the auto-replicative extra-chromosomal nucleic acid molecule under conditions allowing only host that has received said auto-replicative extra-chromosomal nucleic acid molecule to survive, thus providing a microbial host comprising an auto-replicative extra-chromosomal nucleic acid molecule.
- the method further comprises transforming the microbial host with said auto-replicative extra-chromosomal nucleic acid molecule prior to or during step a) under conditions allowing only host that has received said auto-replicative extra-chromosomal nucleic acid molecule to survive, thus providing the microbial host comprising the auto-replicative extra-chromosomal nucleic acid molecule.
- the auto-replicative extra-chromosomal nucleic acid molecule transformed into the microbial host optionally comprises the second nucleic acid sequence of step b).
- the microbial host comprising the auto-replicative extra-chromosomal nucleic acid molecule can subsequently be cultured according to step c).
- an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence.
- An auto-replicative extra-chromosomal nucleic acid molecule can exist free of the genome and may be derived from or comprise, consist essentially of, or consist of a plasmid, or episome, minichromosome, or alike. This feature is attractive as a higher number (from one to hundreds of copies or from 10 to 50 copies depending on the plasmid used) of copies of such nucleic acid molecule can be introduced and maintained into the microbial cell host.
- any host can be used in the methods of embodiments herein.
- an auto-replicative extra-chromosomal nucleic acid molecule usually comprises an origin of replication, a first nucleic acid sequence which is of interest and a regulatory region.
- a first nucleic acid sequence encoding an immunity modulator acts as a selectable marker to maintain the presence and function of the auto-replicative extra-chromosomal nucleic acid in the host cell.
- the first nucleic acid sequence encoding the immunity modulator maintains the presence of the auto-replicative extra-chromosomal nucleic acid so that a product can be produced.
- the product can alter the environment in which the host is present, for example by fermenting a substance in the environment to produce one or more new substances.
- genetic drift is minimized by providing selective pressure against auto-replicative extra-chromosomal nucleic acids that have acquired mutations, and do not produce a functional immunity modulator, produce an immunity modulator with reduced function, and/or produced lower levels of immunity modulator than an auto-replicative extra-chromosomal nucleic acid that has not acquired the mutation(s).
- the first nucleic acid molecule represented by the first nucleic acid sequence is able to exhibit a genetic activity, said genetic activity confering an selective advantage to the microbial host cell wherein it is present and wherein this genetic activity is expressed.
- This genetic activity is provided by the product encoded by the first nucleic acid molecule.
- this genetic activity can be controlled or is expressed constitutively at a low level or is tunable or is under the control of a weak constitutive promoter. The control of said activity is believed to provide an advantage to limit the burden of energy for the host.
- an advantage to limit the energy burden of the host may be obtained when the genetic activity is expressed constitutively at a low level or is tunable or is under the control of a weak constitutive promoter.
- the concept “conferring an advantage” may be replaced by “conferring immunity to a bacteriocin” or “conferring resistance to a bacteriocin”.
- the first nucleic acid sequence encodes an immunity modulator as described herein, and thereby confers an advantage to the host.
- the product of interest comprises an enzyme that is useful in an industrial process, for example a fermentation process.
- the fermentation process can ferment at least one compound in the culture medium.
- the product of interest comprises an industrially useful molecule, for example a carbohydrate, a lipid, an organic molecule, a nutrient, a fertilizer, a biofuel, a cosmetic (or precursor thereof), a pharmaceutical or biopharmaceutical product (or precursor thereof), or two or more of any of the listed items.
- a genetic activity may mean any activity that is caused by or linked with the presence of the first nucleic acid molecule in a microbial host.
- the advantage of said activity may be the ability to survive or survive and grow under given conditions (pH, temperature, presence of a given molecule such as a bacteriocin or combination of two or more bacteriocins as described herein, . . . ). Accordingly the advantage of said activity may be assessed by determining the number of microbial cells/hosts comprising the auto-replicative extrachromosomal nucleic acid molecule.
- the assessment may be carried out at the end of and/or during the optional transforming step (but prior to culturing step c), or prior to steps a) and culturing step c)) and/or prior to culturing step c).
- the number of microbial host cells comprising the auto-replicative extra-chromosomal nucleic acid molecule present has not been decreased and may be increased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to the number of initial microbial cells/host when the cells are being cultured under conditions allowing the microbial host that has received said auto-replicative extra-chromosomal nucleic acid molecule to survive (e.g., by possessing immunity to one or more
- the control of a genetic activity may mean either an increase or decrease of activity of a nucleic acid molecule (i.e. first and/or second nucleic acid molecule). Accordingly, the control of a genetic activity can be controlled or is expressed constitutively at a low level or is tunable or is under the control of a weak constitutive promoter.
- the coding product for which genetic activity is regulated/controlled comprises, consists essentially of, or consists of an immunity modulator or is involved in the production of a product of interest. In some embodiments, genetic activity is regulated/controlled at the level of gene expression.
- genetic activity is regulated at the transcriptional level, for example by activating or repressing a promoter.
- promoters in this context are inducible promoters.
- promoters in this context are weak promoters. Without being limited by theory, weak promoters of some embodiments can be amendable to up- or down-regulating the level of transcription so that the advantage conferred to the host (e g immunity modulator activity) is sensitive to changes in levels and/or activity of the gene product(s) under the control of the promoter.
- the promoter comprises, consists of, or consists essentially of the P24 promoter represented by SEQ ID NO:707 and/or the ProC promoter represented by SEQ ID NO: 708 and/or the P24 LacO hybrid promoter.
- the P24LacO hybrid promoter is a tunable/controlled promoter.
- gene activity is regulated/controlled at the post-transcriptional level, for example through regulation of RNA stability.
- genetic activity is regulated/controlled at the translational level, for example through regulation of initiation of translation.
- genetic activity is regulated/controlled at the post-translational level, for example through regulation of polypeptide stability, post-translational modifications to the polypeptide, or binding of an inhibitor to the polypeptide.
- genetic activity is increased.
- activity of at least one of an immunity modulator and/or the coding product of the second nucleic acid molecule is involved in the production of a product of interest is increased.
- genetic activity can be increased by directly activating genetic activity, or by decreasing the activity of an inhibitor of genetic activity.
- genetic activity is activated by at least one of: inducing promoter activity, inhibiting a transcriptional repressor, increasing RNA stability, inhibiting a post-transcriptional inhibitor (for example, inhibiting a ribozyme or antisense oligonucleotide), inducing translation (for example, via a regulatable tRNA), making a desired post-translational modification, or inhibiting a post-translational inhibitor (for example a protease directed to a polypeptide encoded by the gene).
- a compound present in a desired environment induces a promoter.
- the presence of iron in culture medium can induce transcription by an iron-sensitive promoter as described herein.
- a compound present in a desired culture medium inhibits a transcriptional repressor.
- the presence of tetracycline in an environment can inhibit the tet repressor, and thus allow activity from the tetO promoter.
- a compound found only outside of a desired culture medium induces transcription.
- genetic activity is decreased.
- genetic activity can be decreased by directly inhibiting genetic activity, or by decreasing the activity of an activator of genetic activity.
- genetic activity is reduced, but some level of activity remains. In some embodiments, genetic activity is fully inhibited.
- genetic activity is decreased by at least one of inhibiting promoter activity, activating a transcriptional repressor, decreasing RNA stability, activating a post-transcriptional inhibitor (for example, expressing a ribozyme or antisense oligonucleotide), inhibiting translation (for example, via a regulatable tRNA), failing to make a required post-translational modification, inactivating a polypeptide (for example by binding an inhibitor or via a polypeptide-specific protease), or failing to properly localize a polypeptide.
- a post-transcriptional inhibitor for example, expressing a ribozyme or antisense oligonucleotide
- inhibiting translation for example, via a regulatable tRNA
- inactivating a polypeptide for example by binding an inhibitor or via a polypeptide-specific protease
- genetic activity is decreased by removing a gene from a desired location, for example by excising a gene using a FLP-FRT or cre-lox cassette, homologous recombination or CRIPR-CAS9 activity or through loss or degradation of a plasmid.
- a gene product e.g. a polypeptide
- a product produced by a gene product e.g. the product of an enzymatic reaction
- inhibits further gene activity e.g. a negative feedback loop.
- the advantage conferred to a microbial host by the genetic activity of the first nucleic acid molecule is the ability to survive or survive and grow in a medium comprising a bacteriocin (or a mix of bacteriocins).
- bacteriocin encompasses a cell-free or chemically synthesized version of such a polypeptide.
- a “bacteriocin,” and variations of this root term, may also refer to a polypeptide that had been secreted by a host cell.
- a bacteriocin therefore encompasses a proteinaceous toxin produced by bacteria to inhibit the growth of similar or closely related bacterial strain(s).
- a bacteriocin also encompasses a synthetic variant of a bacteriocin secreted by a host cell.
- Synthetic variant of a bacteriocin may be derived from the bacteriocin secreted by a host cell in any way as long as the synthetic variant still exhibits at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 901 ⁇ of the activity of the corresponding bacteriocin secreted by a host cell.
- a “bacteriocin” can neutralize at least one cell other than the individual host cell in which the polypeptide is made, including cells clonally related to the host cell and other microbial cells.
- a cell that expresses a particular “immunity modulator” is immune to the neutralizing effects of a particular bacteriocin or group of bacteriocins.
- bacteriocins can neutralize a cell producing the bacteriocin and/or other microbial cells, so long as these cells do not produce an appropriate immunity modulator.
- a bacteriocin can exert cytotoxic or growth-inhibiting effects on a plurality of other microbial organisms.
- a bacteriocin is produced by the translational machinery (e.g. a ribosome, etc.) of a microbial cell.
- a bacteriocin is chemically synthesized.
- bacteriocins can be derived from a polypeptide precursor.
- the polypeptide precursor can undergo cleavage (for example processing by a protease) to yield the polypeptide of the bacteriocin itself.
- a bacteriocin is produced from a precursor polypeptide.
- a bacteriocin comprises, consists essentially of, or consists of a polypeptide that has undergone post-translational modifications, for example cleavage, or the addition of one or more functional groups.
- Neutralizing activity of bacteriocins can include arrest of microbial reproduction, or cytotoxicity.
- Some bacteriocins have cytotoxic activity (e.g. “bacteriocide” effects), and thus can kill microbial organisms, for example bacteria, yeast, algae, synthetic micoorganisms, and the like.
- Some bacteriocins can inhibit the reproduction of microbial organisms (e.g. “bacteriostatic” effects), for example bacteria, yeast, algae, synthetic micoorganisms, and the like, for example by arresting the cell cycle.
- bacteriocins A number of bacteriocins have been identified and characterized (see tables 1.1 and 1.2.). Without being limited by any particular theory, exemplary bacteriocins can be classified as “class I” bacteriocins, which typically undergo post-translational modification, and “class II” bacteriocins, which are typically unmodified. Additionally, exemplary bacteriocins in each class can be categorized into various subgroups, as summarized in Table 1.1, which is adapted from Cotter, P. D. et al. “Bacteriocins—a viable alternative to antibiotics” Nature Reviews Microbiology 11: 95-105, hereby incorporated by reference in its entirety.
- bacteriocins can effect neutralization of a target microbial cell in a variety of ways.
- a bacteriocin can permeabilize a cell wall, thus depolarizing the cell wall and interfering with respiration.
- Table 1.1 Classification of Exemplary Bacteriocins.
- bacteriocins can be used in accordance with embodiments herein. Exemplary bacteriocins are shown in Table 1.2. In some embodiments, at least one bacteriocin comprising, consisting essentially of, or consisting of a polypeptide sequence of Table 1.2 is provided. As shown in Table 1.2, some bacteriocins function as pairs of molecules. As such, it will be understood that unless explicity stated otherwise, when a functional “bacteriocin” or “providing a bacteriocin,” or the like is discussed herein, functional bacteriocin pairs are included along with bacteriocins that function individually. With reference to Table 1.2, “organisms of origin” listed in parentheses indicate alternative names and/or strain information for organisms known to produce the indicated bacteriocin.
- Embodiments herein also include peptides and proteins with identity to bacteriocins described in Table 1.2.
- identity is meant to include nucleic acid or protein sequence homology or three-dimensional homology.
- a vast range of functional bacteriocins can incorporate features of bacteriocins disclosed herein, thus providing for a vast degree of identity to the bacteriocins in Table 1.2.
- a bacteriocin has at least 50% identity, for example, at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the polypeptides of Table 1.2.
- Percent identity may be determined using the BLAST software (Altschul, S. F., et al. (1990) “Basic local alignment search tool.” J. Mol. Biol. 215:403-410, accessible on the world wide web at blast.ncbi.nlm.nih.gov) with the default parameters.
- bacteriocins in Table 1.2 are naturally-occurring, the skilled artisan will appreciate that variants of the bacteriocins of Table 1.2, naturally-occurring bacteriocins other than the bacteriocins of Table 1.2 or variants thereof, or synthetic bacteriocins can be used according to some embodiments herein. In some embodiments, such variants have enhanced or decreased levels of cytotoxic or growth inhibition activity on the same or a different microorganism or species of microorganism relative to the wild type protein. Several motifs have been recognized as characteristic of bacteriocins.
- a synthetic bacteriocin comprises an N-terminal sequence with at least 50% identity to SEQ ID NO: 2, for example at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 2.
- a synthetic bacteriocin comprises a N-terminal sequence comprising SEQ ID NO: 2.
- some class lib bacteriocins comprise a GxxxG motif (x means any amino acid). Without being limited by any particular theory, it is believed that the GxxxG motif can mediate association between helical proteins in the cell membrane, for example to facilitate bacteriocin-mediated neutralization through cell membrane interactions.
- the bacteriocin comprises a motif that facilitates interactions with the cell membrane.
- the bacteriocin comprises a GxxxG motif.
- the bacteriocin comprising a GxxxG motif can comprise a helical structure.
- “bacteriocin” as used herein also encompasses structures that have substantially the same effect on microbial cells as any of the bacteriocins explicitly provided herein.
- fusion polypeptides comprising, consisting essentially of, or consisting of two or more bacteriocins or portions thereof can have neutralizing activity against a broader range of microbial organisms than either individual bacteriocin.
- a hybrid bacteriocin, Ent35-MccV GKYYGNGVSCNKKGCSVDWGRAIGIIGNNSAANLATGGAAGWKSGGGASGR DIAMAIGTLSGQFVAGGIGAAAGGVAGGAIYDYASTHKPNPAMSPSGLGGTIK QKPEGIPSE AWNYAAGRLCNWSPNNLSDVCL, SEQ ID NO: 3
- displays antimicrobial activity against pathogenic Gram-positive and Gram-negative bacteria displays antimicrobial activity against pathogenic Gram-positive and Gram-negative bacteria (Acuna et al.
- Ent35-MccV fusion bacteriocin comprises, from N-terminus to C-terminus, an N-terminal glycine, Enterocin CRL35, a linker comprising three glycines, and a C-terminal Microcin V.
- bacteriocins can comprise fusions of two or more polypeptides having bacteriocin activity.
- a fusion polypeptide of two or more bacteriocins is provided.
- the two or more bacteriocins comprise, consist essentially of, or consist of polypeptides from Table 1.2, or modifications thereof.
- the fusion polypeptide comprising of two or more bacteriocins has a broader spectrum of activity than either individual bacteriocin, for example having neutralizing activity against more microbial organisms, neutralizing activity under a broader range of environmental conditions, and/or a higher efficiency of neutralization activity.
- a fusion of two or more bacteriocins is provided, for example two, three, four, five, six, seven, eight, nine, or ten bacteriocins.
- two or more bacteriocin polypeptides are fused to each other via a covalent bond, for example a peptide linkage.
- a linker is positioned between the two bacteriocin polypeptides.
- the linker comprises, consists essentially of, or consists of one or more glycines, for example about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 glycines.
- the linker is cleaved within the cell to produce the individual bacteriocins included in the fusion protein.
- a bacteriocin as provided herein is modified to provide a desired spectrum of activity relative to the unmodified bacteriocin.
- the modified bacteriocin may have enhanced or decreased activity against the same organisms as the unmodified bacteriocin.
- the modified bacteriocin may have enhanced activity against an organism against which the unmodified bacteriocin has less activity or no activity.
- lactis 153 A1 Streptococcus lactis 154 Lacticin 3147 Lantibiotic Lactococcus lactis subsp.
- lactis 155 A2 Streptococcus lactis 156 Lacticin 481 Lantibiotic Lactococcus lactis subsp.
- lactis 157 (Lactococcin ( Streptococcus lactis ) DR) 158 Lacticin Q Unclassified Lactococcus lactis 159 160 Lacticin Z Unclassified Lactococcus lactis 161 162 Lactobin-A class IIB Lactobacillus amylovorus 163 (Amylovorin- L471) 164 Lactocin-S Lantibiotic Lactobacillus sakei L45 165 166 Lactococcin 972 Unclassified Lactococcus lactis subsp. lactis 167 ( Streptococcus lactis ) 168 Lactococcin-A Unclassified Lactococcus lactis subsp.
- cremoris 169 Streptococcus cremoris 170 Lactococcin-B Unclassified Lactococcus lactis subsp.
- cremoris 171 Streptococcus cremoris 172 Lactocyclicin Q Unclassified Lactococcus sp. QU 12 173 174 Laterosporulin Unclassified Brevibacillus sp.
- lactis 219 ( Streptococcus lactis ) 220 Nisin F Lantibiotic Lactococcus lactis 221 222 Nisin Q Lantibiotic Lactococcus lactis 223 224 Nisin U Lantibiotic Streptococcus uberis 225 226 Nisin Z Lantibiotic Lactococcus lactis subsp.
- lactis 227 Streptococcus lactis ) 228 Nukacin ISK-1 Lantibiotic Staphylococcus warneri 229 230 Paenicidin A Lantibiotic Paenibacillus polymyxa ( Bacillus 231 polymyxa ) 232 Pediocin PA-1 class IIA/YGNGV Pediococcus acidilactici 233 (Pediocin ACH) 234 Penocin A class IIA/YGNGV Pediococcus pentosaceus (strain 235 ATCC 25745/183-1w) 236 Pep5 Lantibiotic Staphylococcus epidermidis 237 238 Piscicolin 126 class IIA/YGNGV Carnobacterium maltaromaticum 239 ( Carnobacterium piscicola ) 240 Plantaricin 1.25 Unclassified Lactobacillus plantarum 241 ⁇ 242 Plantaricin 423 class IIa Lactobacillus plantarum 243
- lactis 349 Streptococcus lactis ) 350 Ancovenin Lantibiotic Streptomyces sp. (strain A647P-2) 351 352 Actagardine Lantibiotic Actinoplanes liguriae 353 (Gardimycin) 354 Curvaticin FS47 Unclassified Lactobacillus curvatus 355 356 Bavaricin-MN class IIA/YGNGV Lactobacillus sakei 357 358 Mutacin B- Lantibiotic Streptococcus mutans 359 Ny266 360 Mundticin class IIA/YGNGV Enterococcus mundtii 361 362 Bavaricin-A class IIA/YGNGV Lactobacillus sakei 363 364 Lactocin-705 Class IIb Lactobacillus paracasei 365 366 Leucocin-B Unclassified Leuconostoc mesenteroides 367 368 Leucocin C class IIA/YGNGV Le
- an anti-fungal activity (such as anti-yeast activity) is desired.
- a number of bacteriocins with anti-fungal activity have been identified.
- bacteriocins from Bacillus have been shown to have neutralizing activity against yeast strains ⁇ see Adetunji and Olaoye (2013) Malaysian Journal of Microbiology 9: 130-13, hereby incorporated by reference in its entirety)
- an Enterococcus faecalis peptide WLPPAGLLGRCGRWFRPWLLWLQ SGAQY KWLGNLFGLGPK, SEQ ID NO: 1
- WLPPAGLLGRCGRWFRPWLLWLQ SGAQY KWLGNLFGLGPK SEQ ID NO: 1
- bacteriocins from Pseudomonas have been shown to have neutralizing activity against fungi such as Curvularia lunata, Fusarium species, Helminthosporium species, and Biopolaris species (Shalani).
- subtilis In Bacillus subtilis and Other Gram-Positive Bacteria: Biochemistry, Physiology, and Molecular Genetics ed Sonenshein et al., pp. 897-916, American Society for Microbiology, hereby incorporated by reference in its entirety) and alirin B1 ⁇ see Shenin et al. (1995) Antibiot Khimioter 50: 3-7, hereby incorporated by reference in its entirety) from 5. subtilis have been shown to have antifungal activities. As such, in some embodiments, for example embodiments in which neutralization of a fungal microbial organism is desired, a bacteriocin comprises at least one of botrycidin AJ1316 or alirin B1.
- bacteriocin activity in a culture of cyanobacteria is desirable.
- bacteriocins are provided to neutralize cyanobacteria.
- bacteriocins are provided to neutralize invading microbial organisms typically found in a cyanobacteria culture environment. Clusters of conserved bacteriocin polypeptides have been identified in a wide variety of cyanobacteria species. For example, at least 145 putative bacteriocin gene clusters have been identified in at least 43 cyanobacteria species, as reported in Wang et al.
- cyanobacteria bacteriocins are shown in Table 1.2 as SEQ ID NO's 420, 422, 424, 426, 428, 30, 432, 434, 436, 438, 440, 442, 444, 446, 448, and 450.
- a bacteriocin may work via different mechanisms on a microbial cell as explained herein, a bacteriocin may be said to be active when the number of microbial host has decreased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to the number of initial microbial host when the microbial hosts are being cultured with a medium comprising a bacteriocin.
- This culture step may have a duration of at least 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours or more before assessing the activity of the bacteriocin by counting the number of microbial hosts present.
- the activity may be assessed by counting the cells under the microscope or by any known microbial techniques.
- a bacteriocin is active when the growth has been arrested in at least a specified number or percentage of microbial hosts, for example at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, or at least 95% of the microbial hosts arrested compared to the initial population of microbial hosts when the microbial hosts are being cultured with a medium comprising a bacteriocin.
- the bacteriocin is B17 or C7 represented by an amino acid sequence comprising or consisting of SEQ ID NO: 198 or 200 respectively.
- B17 and C7 have been experimentally confirmed to be selection agents simple to produce, easy to use and stable in culture medium in accordance with some embodiments herein (See Example 1).
- Some of methods, uses, compositions, hosts, and nucleic acids of embodiments herein also encompass the use a bacteriocin having at least 50% identity to SEQ ID NO: 198 or 200, for example at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 198 or 200.
- Such variants of B17 or C7 may be used in methods, uses, compositions, hosts, and nucleic acids of embodiments herein as long as they exhibit at least a substantial activity of B17 or C7.
- “substantial” means, for example, at least 50%, at least 60%, at least 705, at least 80%, at least 90%, or at least 100% or more of the activity of B17 or C7 having SEQ ID NO: 198 or 200. The activity of a bacteriocin has been described earlier herein.
- bacteriocin B17 or C7 inventors were able to prepare culture medium comprising said bacteriocin in a concentration which allows one to carry out the methods and uses of embodiments herein, i.e. to observe or visualize an advantage of the expression of said genetic activity.
- the quantity of bacteriocin in said medium or agar plate is such that the number of host that does not comprise said auto-replicative extra-chromosomal has been decreased by at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to the number of initial microbial cells/host when the cells are being cultured under conditions allowing the microbial host that has received said auto-replicative extra-chromosomal nucleic acid molecule to survive and to grow.
- This assessment step may have a duration of at least 6 hours, 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours or more.
- Said culture medium may be sterilized without losing substantial bacteriocin activity.
- substantially means, for example, more than 50%, more than 60%, more than 70%, more than 80%, more than 90% of the bacteriocin activity present in the culture medium before sterilization.
- lactis 473 Streptococcus lactis ) 474 Lactococcin-A immunity modulator Lactococcus lactis subsp. cremoris 475 ( Streptococcus cremoris ) 476 Colicin-D immunity modulator (Microcin-D Escherichia coli 477 immunity modulator) 478 Colicin-E5 immunity modulator (ImmE5) (Microcin- Escherichia coli 479 E5 immunity modulator) 480 Colicin-E6 immunity modulator (ImmE6) (Microcin- Escherichia coli 481 E6 immunity modulator) 482 Colicin-E8 immunity modulator in ColE6 Escherichia coli 483 (E8Imm[E6]) 484 Colicin-E9 immunity modulator (ImmE9) (Microcin- Escherichia coli 485 E9 immunity modulator) 486 Colicin-M immunity modulator (Microcin-M Escherichia
- cremoris 499 Streptococcus cremoris ) 500 Pediocin PA-1 immunity modulator (Pediocin Pediococcus acidilactici 501 ACH immunity modulator) 502 Putative carnobacteriocin-BM1 immunity modulator Carnobacterium maltaromaticum 503 ( Carnobacterium piscicola ) 504 Putative carnobacteriocin-B2 immunity modulator Carnobacterium maltaromaticum 505 (Carnocin-CP52 immunity modulator) ( Carnobacterium piscicola ) 506 Nisin immunity modulator Lactococcus lactis subsp.
- PA-1 immunity modulator Pediocin Pediococcus acidilactici 501 ACH immunity modulator
- 502 Putative carnobacteriocin-BM1 immunity modulator Carnobacterium maltaromaticum 503 ( Carnobacterium piscicola ) 504 Putative carnobacteriocin
- lactis 507 Streptococcus lactis 508 Trifolitoxin immunity modulator Rhizobium leguminosarum bv. trifolii 509 510 Antilisterial bacteriocin subtilosin biosynthesis Bacillus subtilis (strain 168) 511 protein AlbD 512 Putative ABC transporter ATP-binding protein AlbC Bacillus subtilis (strain 168) 513 (Antilisterial bacteriocin subtilosin biosynthesis protein AlbC) 514 Antilisterial bacteriocin subtilosin biosynthesis Bacillus subtilis (strain 168) 515 protein AlbB 516 Colicin-E7 immunity modulator (ImmE7) (Microcin- Escherichia coli 517 E7 immunity modulator) 518 Pyocin-S1 immunity modulator Pseudomonas aeruginosa 519 520 Pyocin-S2 immunity modulator Pseudomonas aeruginosa (strain ATCC 521 15692
- bacteriocins of Table 2 While the sequence providing immunity to a bacteriocin of Table 2 are naturally-occurring, the skilled artisan will appreciate that variants of such molecules, naturally-occurring molecules other than the ones of Table 2, or synthetic ones can be used according to some embodiments herein.
- Exemplary bacteriocins to which molecules can confer immunity are identified in Table 2.
- immunomodulator or “molecule conferring or providing immunity to a bacteriocin” encompasses not only to structures expressly provided herein, but also structures that have substantially the same effect as the “immunity modulator” structures described herein, including fully synthetic immunity modulators, and immunity modulators that provide immunity to bacteriocins that are functionally equivalent to the bacteriocins disclosed herein.
- Exemplary polynucleotide sequences encoding the polypeptides of Table 2 are indicated in Table 2.
- the genetic code is degenerate, and moreover, codon usage can vary based on the particular organism in which the gene product is being expressed, and as such, a particular polypeptide can be encoded by more than one polynucleotide.
- a polynucleotide encoding a bacteriocin immunity modulator is selected based on the codon usage of the organism expressing the bacteriocin immunity modulator.
- a polynucleotide encoding a bacteriocin immunity modulator is codon optimized based on the particular organism expressing the bacteriocin immunity modulator.
- a vast range of functional immunity modulators can incorporate features of immunity modulators disclosed herein, thus providing for a vast degree of identity to the immunity modulators in Table 2.
- an immunity modulator has at least about 50% identity, for example, at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to any one of the polypeptides of Table 2.
- resistance or immunity to a bacteriocin may mean the number of microbial cells at the end of a culturing step with a bacteriocin has not been decreased, and in some embodiments has been increased of at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or more compared to the number of initial microbial cells when the cells are being cultured with a medium comprising a bacteriocin.
- This culture step may have a duration of at least 12 hours, 24 hours, 36 hours, 48 hours, 60 hours, 72 hours, 84 hours, 96 hours, 108 hours, 120 hours or more before assessing the activity of the bacteriocin by counting the number of microbial cells present.
- a nucleic acid molecule suitable for methods, uses, compositions, hosts, and nucleic acids of some embodiments herein and whose encoding product confers immunity is McbG (Immunity to the bacteriocin B17), which is represented by SEQ ID NO: 699. McbG has been experimentally confirmed to be useful as a selectable marker either constitutively or inducibly in accordance with some embodiments herein (See Example 3).
- MccE IImmunity to the bacteriocin C7 which is represented by SEQ ID NO: 700 or its c-terminal portion, represented by SEQ ID NO: 701.
- MccE had been used as a vector selection marker in strains sensitive to microcines/bacteriocins (See Example 2).
- Methods, uses, compositions, hosts, and nucleic acids of some embodiments also encompass the use of a nucleic acid molecule whose encoding product confers immunity to bacteriocin B17 and/or C7 and having at least 50% identity to SEQ ID NO: 699, 700, or 701, for example at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%,
- McbG and/or MccE may be used in methods, uses, compositions, hosts, and nucleic acids of embodiments herein as long as they exhibit at least a substantial activity of McbG (respectively MccE).
- substantially means, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% or more of the activity of McbG (respectively MccE) having SEQ ID NO: 699, 700 or 701.
- the immunity conferred by the encoding product of McbG (respectively MccE) has been described earlier herein.
- MccE which is represented by SEQ ID NO: 701 is sufficient to confer resistance to bacteriocin C7.
- Part means in this context, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90% or more of the original nucleic acid molecule.
- This is quite attractive and surprising that such a short nucleic acid molecule can confer resistance to a bacteriocin. It is expected that an auto-replicative extra-chromosomal nucleic acid molecule comprising such short nucleic acid molecule does not form any burden for the microbial cell.
- a further suitable nucleic acid molecule for methods, uses, compositions, hosts, and nucleic acids of some embodiments herein, and whose product provides immunity to a bacteriocin is a single nucleic acid molecule whose single product provides immunity to at least two distinct bacteriocins.
- such product of such nucleic acid molecule provides immunity to B17 and C7 or to ColV and C7 or to ColV and B17 or to B17, C7 and ColV.
- a nucleic acid encoding ColV is identified as SEQ ID NO: 65 and a corresponding coding amino acid sequence is identified as SEQ ID NO: 64.
- a nucleic acid molecule whose product provides immunity to B17 and C7 is represented by a sequence having at least 50% identity to SEQ ID NO: 715 or 716 for example at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 715 or 716.
- SEQ ID NO: 715 is a nucleic acid molecule of McbG fused to MccE.
- SEQ ID NO: 716 is a nucleic acid molecule of McbG fused to the C-terminal part of MccE as earlier described herein.
- a nucleic acid molecule whose product provides immunity to ColV and C7 is represented by a sequence having at least 50% identity to SEQ ID NO: 717 or 718 for example at least 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identity to SEQ ID NO: 717 or 718.
- SEQ ID NO: 717 is a nucleic acid molecule of Cvi fused to MccE.
- SEQ ID NO: 718 is a nucleic acid molecule of Cvi fused to the C-terminal part of MccE as earlier described herein.
- identity variants of the core sequence may be used in methods, uses, compositions, hosts, and nucleic acids of embodiments herein as long as they exhibit at least a substantial activity of the molecule they derived from as earlier described herein.
- each of these nucleic acid molecules described herein whose product confers immunity to a single or to more than one or to at least two bacteriocins may be operably linked to a promoter as described herein.
- the promoter is a weak promoter.
- the weak promoter is the proC promoter represented by SEQ ID NO: 708 or the P24 promoter represented by SEQ ID NO: 707, which has been experimentally confirmed (See, e.g. Example 3).
- Suitable constructs useful in methods, uses, compositions, hosts, and nucleic acids of embodiments herein can comprise a first nucleic acid molecule whose product confers immunity to a bacteriocin, and these constructs may comprise, consist essentially of, or consist of SEQ ID NO: 702, 703, 710, 711, 704, 705, 712, 713 or 714.
- SEQ ID NO: 702, 703, 710, 711, 704, 705, 712, 713 or 714 Each of these constructs has been extensively described in the experimental part of the application, which notes that each of these constructs was actually constructed and confirmed to be suitable in accordance with some embodiments herein (See, e.g., Examples 1 and 2 and 3).
- the bacteriocin added to the culture medium is a B17 and/or a C7 and/or a ColV as identified herein
- the method may allow the production of any product of interest.
- the product of interest is a microbial biomass, the auto-replicative extra-chromosomal nucleic acid molecule, the transcript of said second nucleic sequence, a polypeptide encoded by said second sequence or a metabolite produced directly or indirectly by said polypeptide.
- the product of interest is purified at the end of the culturing step c). This may be carried out using techniques known to the skilled person. Since the energetic burden associated with the presence of the auto-replicative extra-chromosomal nucleic acid molecule has been minimized, the yield of the product of interest is expected to be optimal.
- the method may use any suitable microbial cells, for example as hosts.
- Suitable microbial cells are listed in the part of the specification entitled general descriptions. Suitable microbial cells per se and for use in methods, uses, compositions, and hosts of embodiments herein include, but are not limited to: a bacterium (for example, a Gram negative bacterium, for example an E. coli species), a yeast, a filamentous fungus or an algae.
- the microbial cell is a synthetic microbial cell.
- the first nucleic acid sequence present on the auto-replicative extra-chromosomal nucleic acid molecule may be operably linked to a promoter.
- said promoter is a weak promoter.
- said promoter is a constitutive promoter.
- said promoter is inducible.
- said promoter is a weak constitutive promoter.
- said promoter is a weak inducible promoter. The inducibility of said promoter is a way of controlling the presence of the genetic activity of the first nucleic acid sequence. Promoters are well known in the art. A detailed description is provided in the part of the specification dedicated to the general descriptions.
- a promoter can be used to drive the transcription of one or more coding sequences.
- said auto-replicative extra-chromosomal nucleic acid molecule comprises a second nucleic acid sequence that is involved in the production of a product of interest, wherein the genetic activity of said second nucleic acid sequence is controlled independently from the one of the first sequence.
- control of the genetic activity of said second nucleic acid sequence is not independent from the control of the genetic activity of the first sequence.
- a second promoter drives expression of said second nucleic acid sequence being involved in the production of a product of interest as described herein.
- a first promoter drives expression of an immunity modulator polynucleotide as described herein.
- a promoter that could be used herein may be not native to a nucleic acid molecule to which it is operably linked, i.e. a promoter that is heterologous to the nucleic acid molecule (coding sequence) to which it is operably linked.
- a promoter of some embodiments is heterologous to a coding sequence to which it is operably linked
- a promoter is homologous, e.g., endogenous to a microbial cell.
- a heterologous promoter (to the nucleotide sequence) is capable of producing a higher steady state level of a transcript comprising a coding sequence (or is capable of producing more transcript molecules, i.e.
- promoters can drive transcription at all times (“constitutive promoters”). Some promoters can drive transcription under only select circumstances (“conditional promoters” or “inducible promoter”), for example depending on the presence or absence of an environmental condition, chemical compound, gene product, stage of the cell cycle, or the like.
- an appropriate promoter can be selected, and placed in cis (i.e. or is operably linked with) with a sequence to be expressed.
- Exemplary promoters with exemplary activities are provided in Table 3.1-3.11 herein.
- Some promoters are compatible with particular transcriptional machinery (e.g. RNA polymerases, general transcription factors, and the like).
- promoters are identified for some promoters described herein, it is contemplated that according to some embodiments herein, these promoters can readily function in microorganisms other than the identified species, for example in species with compatible endogenous transcriptional machinery, genetically modified species comprising compatible transcriptional machinery, or fully synthetic microbial organisms comprising compatible transcriptional machinery.
- the promoters of Tables 3.1-3.11 herein are publicly available from the Biobricks foundation. It is noted that the Biobricks foundation encourages use of these promoters in accordance with BioBrickTM Public Agreement (BPA).
- BPA BioBrickTM Public Agreement
- any of the “coding” polynucleotides described herein is generally amenable to being expressed under the control of a desired promoter.
- a first nucleic acid sequence is under the control of a first promoter.
- a second nucleic acid sequence involved in the production of a product of interest is under the control of a second promoter.
- translation initiation for a particular transcript is regulated by particular sequences at 5′ end of the coding sequence of a transcript.
- a coding sequence can begin with a start codon configured to pair with an initiator tRNA.
- Met a start codon
- an initiator tRNA can be engineered to bind to any desired triplet or triplets, and accordingly, triplets other than AUG can also function as start codons in certain embodiments.
- sequences near the start codon can facilitate ribosomal assembly, for example a Kozak sequence ((gcc)gccNccAUGG, SEQ ID NO: 542, in which N represents “A” or “G”) or Internal Ribosome Entry Site (IRES) in typical eukaryotic translational systems, or a Shine-Dalgarno sequence (GGAGGU, SEQ ID NO: 543) in typical prokaryotic translation systems.
- a transcript comprising a “coding” polynucleotide sequence for example a first nucleic acid sequence, or second nucleic acid sequence involved in the production of a fermentation product, comprises an appropriate start codon and translational initiation sequence.
- each polynucleotide sequence comprises an appropriate start codon and translational initiation sequence(s).
- a translational intiator tRNA is regulatable, so as to regulate initiation of translation of an immunity modulator or industrially useful molecule.
- aureus 556 BBa_I751501 plux-cI hybrid promoter 557 BBa_I751502 plux-lac hybrid promoter 558 BBa_I761011 CinR, CinL and glucose controlled promotor 559 BBa_J06403 RhIR promoter repressible by CI 560 BBa_J102001 Reverse Lux Promoter 561 BBa_J64000 rhlI promoter 562 BBa_J64010 lasI promoter 563 BBa_J64067 LuxR + 3OC6HSL independent R0065 564 BBa_J64712 LasR/LasI Inducible & RHLR/RHLI repressible Promoter 565 BBa_K091107 pLux/cI Hybrid Promoter 566 BBa_K091117 pLas promoter 567 BBa_K091143 pLas/cI Hybrid Promoter 568 BBa_K091146 pLas/L
- T7 SEQ ID NO: Name Description 668 BBa_I712074 T7 promoter (strong promoter from T7 bacteriophage) 669 BBa_I719005 T7 Promoter 670 BBa_J34814 T7 Promoter 671 BBa_J64997 T7 consensus ⁇ 10 and rest 672 BBa_K113010 overlapping T7 promoter 673 BBa_K113011 more overlapping T7 promoter 674 BBa_K113012 weaken overlapping T7 promoter 675 BBa_R0085 T7 Consensus Promoter Sequence 676 BBa_R0180 T7 RNAP promoter 677 BBa_R0181 T7 RNAP promoter 678 BBa_R0182 T7 RNAP promoter 679 BBa_R0183 T7 RNAP promoter 680 BBa_Z0251 T7 strong promoter 681 BBa_Z0252
- a promoter may be a synthetic promoter.
- Suitable promoters for methods, uses, compositions, hosts, and nucleic acids of some embodiments herein have been described earlier herein e.g., proC represented by SEQ ID NO: 708 which has been experimentally confirmed in accordance with some embodiments herein (See Example 2) and P24 represented by SEQ ID NO: 707 which has been experimentally confirmed in accordance with some embodiments herein (See Example 3).
- a suitable inducible promoter is the P24 LacO hybrid promoter, which is repressed in the presence of Lad and active in presence of IPTG. This promoter has been experimentally confirmed in accordance with some embodiments herein (See Example 3).
- a variant, fully synthetic or synthetic or engineer promoter is said to be active or functional and can therefore be used in methods, uses, compositions, hosts, and nucleic acids of embodiments herein when tested in a control or reference plasmid being operably linked with a nucleic acid molecule encoding a transcript, a detectable amount of said transcript molecule is present when said plasmid is present in a cell.
- a variant, fully synthetic or synthetic or engineer promoter may have at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or at least 100% of the activity of the promoter it derives from.
- the method comprises transforming said microbial host with said auto-replicative extra-chromosomal nucleic acid molecule under conditions allowing the host that has received said auto-replicative extra-chromosomal nucleic acid molecule to survive.
- the auto-replicative extra-chromosomal nucleic acid molecule can be provided in a microbial cell (e.g., if the microbial cell, or a predecessor thereof was transformed with the auto-replicative extra-chromosomal nucleic acid molecule), and as such, in some embodiments, the transformation step is not needed in the method. The transforming step can be performed prior to the culturing of step c).
- the transforming step is provided prior to step a) so as to provide the host cell comprising the auto-replicative extra-chromosomal nucleic acid molecule.
- the auto-replicative extra-chromosomal nucleic acid molecule used in the transforming step further comprises the second nucleic acid of optional step b).
- a microorganism is genetically modified to comprise said auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence and optionally a molecule involved in the production of a product of interest.
- Polynucleotides or nucleic acid molecules can be delivered to microorganisms.
- a microbial cell is positively selected for by the genetic activity of the first nucleic acid sequence corresponding to at least one given condition allowing the cell that has received the said auto-replicative extra-chromosomal nucleic acid molecule to survive and said conditions can be environmental conditions.
- Environmental conditions may be a culture medium.
- a cassette for inserting one or more desired distinct first nucleic acid sequences is provided.
- Exemplary cassettes include, but are not limited to, a Cre/lox cassette or FLP/FRT cassette.
- a microbial cell comprises more than one (more than two, more than three, . . . ) different auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence as described herein, meaning that said cell can exhibit more than one (more than two, more than three, . . . ) genetic activity, each genetic activity conferring an advantage to the cell. If a first promoter is present in each of the different auto-replicative extra-chromosomal nucleic acid molecule, each of said first promoters may be different or identical.
- plasmid conjugation can be used to introduce a desired plasmid from a “donor” microbial cell to a recipient microbial cell.
- plasmid conjugation can genetically modify a recipient microbial cell by introducing a conjugation plasmid from a donor microbial cell to a recipient microbial cell.
- conjugation plasmids that comprise the same or functionally same set of replication genes typically cannot coexist in the same microbial cell.
- plasmid conjugation “reprograms” a recipient microbial cell by introducing a new conjugation plasmid to supplant another conjugation plasmid that was present in the recipient cell.
- plasmid conjugation is used to engineer (or reengineer) a microbial cell with a particular combination of first nucleic acid molecules (which can code for immunity modulators in some embodiments).
- first nucleic acid molecules which can code for immunity modulators in some embodiments
- plasmid conjugation comprising different combinations of first acid sequence (which can code for immunity modulators in some embodiments) is provided.
- the plasmids can comprise additional genetic elements as described herein, for example promoters, translational initiation sites, and the like.
- the variety of conjugation plasmids is provided in a collection of donor cells, so that a donor cell comprising the desired plasmid can be selected for plasmid conjugation.
- a particular combination of immunity modulators is selected, and an appropriate donor cell is conjugated with a microbial cell of interest to introduce a conjugation plasmid comprising that combination into a recipient cell.
- the recipient cell is a “newly engineered” cell, for example to be introduced into or for initiating a culture.
- the method further comprises optional step b) wherein said auto-replicative extra-chromosomal nucleic acid molecule comprises a second nucleic acid sequence that is involved in the production of said product of interest, wherein the genetic activity of said second nucleic acid sequence is controlled independently from the one of the first sequence.
- control independently has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, including meaning that distinct ways are used for controlling the genetic activity of the first and the second nucleic acid sequences. Ways of controlling the genetic activity of a nucleic acid sequence have been already described in detail herein.
- step a) (which optionally includes transforming as described herein) and optional step b) is followed by step c), which comprises culturing said transformed microbial host under conditions allowing said transformed microbial host to express the first nucleic acid sequence to a given level to maintain the auto-replicative extra-chromosomal molecule into the growing microbial population.
- step c optionally controlling the second sequence coding for said product of interest.
- step c) at least part of step c) conditions are such that the first nucleic acid sequence does not exhibit said genetic activity.
- Part of step c) means, for example, at least 20%, 30%, 40%, 50%, 60%, 70%, 80% or 90% or up to 100% of the duration of step c).
- This embodiment of the method is quite attractive as part of step c) is carried out without the presence of the genetic activity of the first nucleic acid sequence. The presence of said genetic activity forms an energetic burden for the microbial host cell and is not always needed in order to keep a suitable production level of a product of interest. It is envisaged in some embodiments to have part of step c) without genetic activity of the first nucleic acid sequence followed by a part with said activity. These two parts may be repeated one or more time during step c).
- a microbial cell may be cultured in any suitable microbial culture environment.
- Microbial culture environments can comprise a wide variety of culture media, for example feedstocks.
- the selection of a particular culture medium can depend upon the desired application. Conditions of a culture medium include not only chemical composition, but also temperature, amounts of light, pH, CO 2 levels, and the like.
- the culture medium can comprise a bacteriocin.
- a compound that induces the activity of the bacteriocin is present outside of the feedstock, but not in the feedstock.
- a genetically engineered or transformed microorganism as described herein is added to a culture medium that comprises at least one feedstock.
- the culture medium comprises a compound that induces the activity or expression of an immunity modulator.
- feedstock has is customary and ordinary meaning as understood by one of skill in the art in view of this disclosure, and encompasses material that can be consumed, fermented, purified, modified, or otherwise processed by microbial organisms, for example in the context of industrial processes. As such, “feedstock” is not limited to food or food products. As used herein a “feedstock” is a category of culture medium. Accordingly, as used herein “culture medium” includes, but it is not limited to feedstock. As such, whenever a “culture medium” is referred to herein, feedstocks are also expressly contemplated.
- a microbial cell or microbial host or microbial host cell or synthetic microbial host cell comprising an auto-replicative extra-chromosomal nucleic acid molecule is provided, comprising a first nucleic acid sequence whose genetic activity confers an advantage to a microbial host wherein the genetic activity of said first nucleic acid sequence is controlled, and optionally comprising a second nucleic acid sequence that is directly or indirectly involved in the production of a product of interest.
- an auto-replicative extra-chromosomal nucleic acid molecule comprising a first nucleic acid sequence whose genetic activity confers an advantage to a microbial host wherein the genetic activity of said first nucleic acid sequence is controlled, and optionally comprising a second nucleic acid sequence that is directly or indirectly involved in the production of a product of interest.
- microbial organism As used herein, “microbial organism,” “microorganism,” “microbial cell” or “microbial host” and variations of these root terms (such as pluralizations and the like) have their customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, including any naturally-occurring species or synthetic or fully synthetic prokaryotic or eukaryotic unicellular organism, as well as Archae species. Thus, this expression can refer to cells of bacterial species, fungal species, and algae. Exemplary microorganisms that can be used in accordance with embodiments herein include, but are not limited to, bacteria, yeast, filamentous fungi, and algae, for example photosynthetic microalgae.
- microorganism genomes can be synthesized and transplanted into single microbial cells, to produce synthetic microorganisms capable of continuous self-replication (see Gibson et al. (2010), “Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome,” Science 329: 52-56, hereby incorporated by reference in its entirety).
- the microorganism is fully synthetic.
- a desired combination of genetic elements, including elements that regulate gene expression, and elements encoding gene products for example immunity modulators, poison, antidote, and industrially useful molecules also called product of interest
- product of interest can be assembled on a desired chassis into a partially or fully synthetic microorganism.
- Bacillus species for example Bacillus coagulans, Bacillus subtilis , and Bacillus licheniformis
- Paenibacillus species Streptomyces species, Micrococcus species, Corynebacterium species, Acetobacter species, Cyanobacteria species, Salmonella species, Rhodococcus species, Pseudomonas species, Lactobacillus species, Enterococcus species, Alcaligenes species, Klebsiella species, Paenibacillus species, Arthrobacter species, Corynebacterium species, Brevibacterium species, Thermus aquaticus, Pseudomonas stutzeri, Clostridium thermocellus
- yeast species and strains can be used in accordance with embodiments herein, and genetically modified variants, or synthetic yeast based on a “chassis” of a known species can be provided.
- Exemplary yeast with industrially applicable characteristics include, but are not limited to Saccharomyces species (for example, Saccharomyces cerevisiae, Saccharomyces bayanus, Saccharomyces boulardii ), Candida species (for example, Candida utilis, Candida krusei ), Schizosaccharomyces species (for example Schizosaccharomyces pombe, Schizosaccharomyces japonicas ), Pichia or Hansenula species (for example, Pichia pastoris or Hansenula polymorphd ) species, and Brettanomyces species (for example, Brettanomyces claussenii ).
- Saccharomyces species for example, Saccharomyces cerevisiae, Saccharomyces bayanus, Saccharomyces boulardii
- algae species and strains can be used in accordance with embodiments herein, and genetically modified variants, or synthetic algae based on a “chassis” of a known species can be created.
- the algae comprises, consists essentially of, or consists of photosynthetic microalgae.
- filamentous fungal species and strains can be used in accordance with embodiments herein, and genetically modified variants, or synthetic filamentous fungi based on a “chassis” of a known species can be provided.
- Exemplary filamentous fungi with industrially applicable characteristics include, but are not limited to an Acremonium, Agaricus, Alternaria, Aspergillus, Aureobasidium, Botryosphaeria, Ceriporiopsis, Chaetomidium, Chrysosporium, Claviceps, Cochliobolus, Coprinopsis, Coptotermes, Corynascus, Cryphonectria, Cryptococcus, Diplodia, Exidia, Filibasidium, Fusarium, Gibberella, Holomastigotoides, Humicola, Irpex, Lentinula, Leptospaeria, Magnaporthe, Melanocarpus, Meripilus, Mucor,
- Species include Acremonium cellulolyticus, Aspergillus aculeatus, Aspergillus awamori, Aspergillus foetidus, Aspergillus fumigatus, Aspergillus japonicus, Aspergillus nidulans, Aspergillus niger, Aspergillus oryzae, Chrysosporium inops, Chrysosporium keratinophilum, Chrysosporium lucknowense, Chrysosporium merdarium, Chrysosporium pannicola, Chrysosporium queenslandicum, Chrysosporium tropicum, Chrysosporium zona turn, Fusarium bactridioides, Fusarium cerealis, Fusarium crookwellense, Fusarium culmorum, Fusarium graminearum, Fusarium graminum, Fusarium heterosporum, Fusarium negundi, Fu
- Antibiotic and variations of this root term, have their customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, including a metabolite, or an intermediate of a metabolic pathway which can kill or arrest the growth of at least one microbial cell.
- Some antibiotics can be produced by microbial cells, for example bacteria.
- Some antibiotics can be synthesized chemically. It is understood that bacteriocins are distinct from antibiotics, at least in that bacteriocins refer to gene products (which, in some embodiments, undergo additional post-translational processing) or synthetic analogs of the same, while antibiotics refer to intermediates or products of metabolic pathways or synthetic analogs of the same.
- Sequence identity has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, including a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. Usually, sequence identities or similarities are compared over the whole length of the sequences compared. In the art, “identity” can also refer to the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences. “Similarity” between two amino acid sequences can be determined by comparing the amino acid sequence and its conserved amino acid substitutes of one polypeptide to the sequence of a second polypeptide. “Identity” and “similarity” can be readily calculated by various methods, known to those skilled in the art. In some embodiments, sequence identity is determined by comparing the whole length of the sequences as identified herein.
- Some methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Computer program methods to determine identity and similarity between two sequences include e.g. the BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. Mol. Biol. 215:403-410 (1990), publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894).
- An algorithm used can be EMBOSS (accessible on the world wide web at www(dot)ebi(dot)ac(dot)uk/emboss/align).
- Parameters for amino acid sequences comparison using EMBOSS can include gap open 10.0, gap extend 0.5, Blosum 62 matrix.
- Parameters for nucleic acid sequences comparison using EMBOSS can include gap open 10.0, gap extend 0.5, DNA full matrix (DNA identity matrix).
- amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
- Suitable conservative amino acids substitution groups include: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place. In some embodiments, the amino acid change is conservative.
- Suitable conservative substitutions for each of the naturally occurring amino acids include: Ala to ser; Arg to lys; Asn to gln or his; Asp to glu; Cys to ser or ala; Gln to asn; Glu to asp; Gly to pro; His to asn or gln; Ile to leu or val; Leu to ile or val; Lys to arg; gln or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, Val to ile or leu.
- homologous has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, including when used to indicate the relation between a given (recombinant) nucleic acid or polypeptide molecule and a given host organism or host cell, it can be understood to mean that in nature the nucleic acid or polypeptide molecule is produced by a host cell or organisms of the same species, optionally of the same variety or strain. If homologous to a host cell, a nucleic acid sequence encoding a polypeptide will typically be operably linked to another promoter sequence than in its natural environment.
- the term “homologous” has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, and can refer to one single-stranded nucleic acid sequence that may hybridize to a complementary single-stranded nucleic acid sequence.
- the degree of hybridization may depend on a number of factors including the amount of identity between the sequences and the hybridization conditions such as temperature and salt concentration as earlier presented.
- the region of identity can be greater than about 5 bp, the region of identity can be greater than 10 bp.
- two nucleic acid or polypeptides sequences are said to be homologous when they have more than 80% identity.
- heterologous has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, including when used with respect to a nucleic acid (DNA or RNA) or protein, it can refer to a nucleic acid or protein (also named polypeptide or enzyme) that does not occur naturally as part of the organism, cell, genome or DNA or RNA sequence in which it is present, or that is found in a cell or location or locations in the genome or DNA or RNA sequence that differ from that in which it is found in nature.
- Heterologous nucleic acids or proteins are not endogenous to the cell into which it is introduced, but has been obtained from another cell or synthetically or recombinantly produced.
- nucleic acids encode proteins that are not normally produced by the cell in which the DNA is transcribed or expressed.
- exogenous RNA encodes for proteins not normally expressed in the cell in which the exogenous RNA is present.
- Heterologous nucleic acids and proteins may also be referred to as foreign nucleic acids or proteins. Any nucleic acid or protein that one of skill in the art would recognize as heterologous or foreign to the cell in which it is expressed is herein encompassed by the term heterologous nucleic acid or protein.
- heterologous also applies to non-natural combinations of nucleic acid or amino acid sequences, i.e. combinations where at least two of the combined sequences are foreign with respect to each other.
- operably linked has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, and can refer to a linkage of polynucleotide elements (or coding sequences or nucleic acid sequence or nucleic acid molecule) in a functional relationship.
- a nucleic acid sequence is “operably linked” when it is placed into a functional relationship with another nucleic acid sequence.
- a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the coding sequence.
- Operably linked means that the nucleic acid sequences being linked are typically contiguous and, where necessary to join two protein coding regions, contiguous and in reading frame.
- promoter has its customary and ordinary meanings as understood by one of skill in the art in view of this disclosure, and can refer to a nucleic acid fragment that functions to control the transcription of one or more nucleic acid molecules, located upstream with respect to the direction of transcription of the transcription initiation site of the nucleic acid molecule, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences, including, but not limited to transcription factor binding sites, repressor and activator protein binding sites, and any other sequences of nucleotides known to one of skill in the art to act directly or indirectly to regulate/control the amount of transcription from the promoter.
- a “constitutive” promoter is a promoter that is active under most environmental and developmental conditions.
- An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
- the verb “to comprise” and its conjugations is used in its non-limiting sense to mean that items following the word are included, but items not specifically mentioned are not excluded.
- the verb “to consist” may be replaced by “to consist essentially of” meaning that an auto-replicative extra-chromosomal nucleic acid molecule, a microbial host (or a method) as defined herein may comprise additional component(s) (or additional steps) than the ones specifically identified, said additional component(s) (or additional steps) not altering the unique characteristic of the invention.
- reference to an element by the indefinite article “a” or “an” does not exclude the possibility that more than one of the element is present, unless the context clearly requires that there be one and only one of the elements.
- the indefinite article “a” or “an” thus usually means “at least one”.
- SEQ ID NO: 4-698, 720-759 Sequences in tables 1-3 (half DNA/half protein as indicated in the tables)
- SEQ ID NO: 719 vector pUC-ColV
- FIG. 1 Construction: pSyn2-McbE/F: containing the gene McbE and F under Ptac.
- FIG. 2 Construction: pSyn2-McbG: containing the gene McbG under Ptac.
- FIG. 3 Construction: pMcbG 1.1: containing the gene McbG under P24.
- FIG. 4 Construction: pMcbG 1.0: containing the gene McbG under P24 LacO.
- FIG. 5 pBACT5.0 vector
- FIG. 6 pBACT2.0 vector
- FIG. 7 pBACT5.0-mcherry vector
- FIG. 8 Tuning promoter. In the absence of inductor (upper part), repressor can bind to operator and prevent expression of selection gene. In the presence of inductor (lower part), repressor cannot bind to operator allowing expression of selection gene.
- FIG. 9 Comparison of overexpression of protein X in E. coli with KanR (pKan-pLac) and with 2 immunities against microcines C7 and ColV (pBACT6.0-pLac). 5 mg of total extract was analysed in SDS-PAGE.
- FIG. 10 Comparison of overexpression of iota-carrageenase protein in E. coli with KanR (pKan-T7prom) and with 2 immunities against microcines C7 and ColV (pBACT5.0-T7prom). 5 mg of total extract was analysed in SDS-PAGE.
- FIG. 11 Comparison of overexpression of lambda-carrageenase protein in E. coli with KanR (pKan-T7prom) and with 2 immunities against microcines C7 and ColV (pBACT5.0-T7prom). 5 mg of total extract was analysed in SDS-PAGE.
- mice B17 The vector used for producing Mic B17 is described in the table below.
- the vector used for producing Mic C7 is Pp70. This vector is based on pBR322 and bears a ⁇ 6000 bp DNA fragment with the mcc gene cluster (as described in Zukher I et al, Nucleic Acids Research, 2014, Vol. 42, No. 19 11891-11902).
- the vector used for producing ColV is pUC-ColV (SEQ ID NO: 719). This vector is based on pUC57 and bear a ⁇ 5000 bp DNA fragment with the ColV gene cluster. The strains harbouring these recombinant vectors were grown in LB medium at 37° C.
- the fermented medium was centrifuged and the supernatant flit red on a 0.2 micron filter.
- the bacteriocin activity present in the supernatant was estimated by the size of the diffusion inhibition growth on a plate containing a sensitive strain.
- Bacteriocins B17, C7 and ColV produced by fermentation in laboratory are selection agents simple to produce, easy to use and stable in culture medium. These properties are similar to the ones of antibiotics used as classical selection agent.
- the literature has made it possible to determine the elements necessary for the production of the host against the production of its own bacteriocin, also in the case of B17 bacteriocin: McbG for B17, represented by SEQ ID NO: 699 and pumps (McbE and McbF for B17, represented by SEQ ID NO: 703). These genes are known to be necessary (or more precisely involved in protection against the action of bacteriocin B17).
- the literature for the B17 locus does not identify which is or is the sufficient element to give resistance.
- MccE which is represented by SEQ ID NO: 701 is sufficient to confer resistance to bacteriocin C7.
- SEQ ID NO: 710 represents the construct proC-McbG-CterMccE
- SEQ ID NO: 711 represents the construct proC-Cvi-CterMccE
- Example 3 Can we Generate a Selectable Marker Using Little or No Energy from the Bacteria from McbG?
- McbG gene was cloned under a weak promoter P24 (SEQ ID NO: 707).
- the P24 promoter was described in Braatsch S et al, Biotechniques. 2008 Sep.; 45(3):335-7.
- strains used are the following:
- ⁇ DE3 ⁇ sBamHIo ⁇ EcoRI-B int::(lacI::PlacUV5::T7 gene1) i21 ⁇ nin5
- the BL21(DE3) strain was transformed with vector pMcbG1.0 or pMcbG1.1 (see FIG. 3 or 4 ). After transformation, transformants were selected on plates containing B17. Isolated colonies were re-grown and the plasmid they contained was analyzed by gel electrophoresis after treatment with relevant restriction enzymes.
- McbG a weak transcription of McbG is sufficient to give the resistance to B17.
- this selection marker is inducible via the P24 LacO promoter and that the vectors containing this gene gives the phenotype of resistance only in presence of IPTG.
- McbG gene it is possible to use the McbG gene as a selectable marker either constitutively or inducibly. Thus, it is shown that constitutive expression at a low level and inducible expression according to the need during the process, allows to reduce the energy burden for the producing cell, without loss of the plasmid from the producing cell.
- SEQ ID NO: 714 represents the construct used for producing the m-cherry protein. This construct is depicted in FIG. 7 .
- the m-cherry protein was produced and visualised as the bacterial colony turns red on petri dish in the presence of IPTG.
- FIG. 9 shows the comparison of overexpression of protein X in E. coli with KanR (pKan-pLac) and with 2 immunities against microcines C7 and ColV (pBACT6.0-pLac). 5 mg of total extract was analysed in SDS-PAGE.
- FIG. 10 shows the comparison of overexpression of iota-carrageenase protein in E. coli with KanR (pKan-T7prom) and with 2 immunities against microcines C7 and ColV (pBACT5.0-T7prom). 5 mg of total extract was analysed in SDS-PAGE.
- the vector used is based on the pBACT5.0 vector (SEQ ID NO: 712).
- FIG. 11 shows the comparison of overexpression of lambda-carrageenase protein in E. coli with KanR (pKan-T7prom) and with 2 immunities against microcines C7 and ColV (pBACT5.0-T7prom). 5 mg of total extract was analysed in SDS-PAGE. The vector used is based on the pBACT5.0 vector (SEQ ID NO: 712).
- the weak constitutive proC promoter used in this example allows to reduce the energy burden for the host.
Landscapes
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17208600 | 2017-12-19 | ||
EP17208600 | 2017-12-19 | ||
EP17208600.1 | 2017-12-19 | ||
PCT/EP2018/085941 WO2019121983A1 (en) | 2017-12-19 | 2018-12-19 | Fermentation process |
Publications (2)
Publication Number | Publication Date |
---|---|
US20210070812A1 US20210070812A1 (en) | 2021-03-11 |
US11932672B2 true US11932672B2 (en) | 2024-03-19 |
Family
ID=60781747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/955,720 Active 2040-01-24 US11932672B2 (en) | 2017-12-19 | 2018-12-19 | Fermentation process |
Country Status (7)
Country | Link |
---|---|
US (1) | US11932672B2 (ko) |
EP (1) | EP3728292A1 (ko) |
JP (1) | JP2021506328A (ko) |
KR (1) | KR20200116084A (ko) |
CN (1) | CN111757890A (ko) |
BR (1) | BR112020012543A2 (ko) |
WO (1) | WO2019121983A1 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR122021015417B1 (pt) | 2013-08-19 | 2022-11-08 | Syngulon Sa | Célula microbiana geneticamente engenheirada que compreende um ácido nucleico que codifica uma bacteriocina |
JP2021506328A (ja) | 2017-12-19 | 2021-02-22 | シンギュロン・ソシエテ・アノニム | 発酵プロセス |
JP2022545085A (ja) * | 2019-08-19 | 2022-10-25 | ベイラー ユニバーシティ | ガイド抗菌ペプチドのプロバイオティクス送達 |
WO2021064250A2 (en) * | 2019-10-04 | 2021-04-08 | University Of Plymouth | Antimicrobial peptides |
WO2021154872A1 (en) * | 2020-01-27 | 2021-08-05 | General Probiotics, Inc. | Compositions including probiotic bacteria for the expression and secretion of enterocins to control clostridia perfringens-induced necrotic enteritis in livestock and related methods |
WO2023041435A1 (en) * | 2021-09-14 | 2023-03-23 | Syngulon S.A. | Bacteriocin for applications against mycobacterium |
CN114478722B (zh) * | 2022-02-09 | 2023-07-21 | 淮北师范大学 | 一种细菌素Bacin A1及其应用 |
Citations (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0556790A (ja) | 1991-02-26 | 1993-03-09 | Imperial Chem Ind Plc <Ici> | ベクター、非相同ポリペプチドを表現することのできる宿主、その製法、ポリペプチドの製法及び複製可能なプラスミド表現ベヒクル |
WO1994003616A2 (fr) | 1992-07-31 | 1994-02-17 | Universite Libre De Bruxelles | Vecteur de clonage et/ou de sequençage |
US5300431A (en) | 1991-02-26 | 1994-04-05 | E. I. Du Pont De Nemours And Company | Positive selection vector for the bacteriophage P1 cloning system |
US5549895A (en) | 1993-05-17 | 1996-08-27 | Iowa State University Research Foundation, Inc. | Method and colicin composition for inhibiting Escherichia coli 0157:H7 in food products |
WO1997013401A1 (en) | 1995-10-13 | 1997-04-17 | Purdue Research Foundation | Method for the production of hybrid plants |
WO1997014805A2 (en) | 1995-10-17 | 1997-04-24 | Biostar, Inc. | Methods for production of recombinant plasmids |
US5631153A (en) | 1989-08-22 | 1997-05-20 | University Of Utah | Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
US5670370A (en) | 1986-03-26 | 1997-09-23 | Gx Biosystems A/S | Biological containment |
US5855732A (en) | 1994-11-22 | 1999-01-05 | Nec Corporation | Outer lead bonding apparatus and method of bonding lead to substrate |
WO1999002555A1 (en) | 1997-07-09 | 1999-01-21 | The Governors Of The University Of Alberta | Novel bacteriocins, transport and vector system and method of use thereof |
US5888732A (en) | 1995-06-07 | 1999-03-30 | Life Technologies, Inc. | Recombinational cloning using engineered recombination sites |
WO1999021977A1 (en) | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
WO1999058652A2 (en) | 1998-05-07 | 1999-11-18 | Gx Biosystems A/S | Cytotoxin-based biological containment |
US6143557A (en) | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
WO2001031039A1 (en) | 1999-10-25 | 2001-05-03 | Invitrogen Corporation | Methods of manipulating and sequencing nucleic acid molecules using transposition and recombination |
WO2001042509A1 (en) | 1999-12-10 | 2001-06-14 | Invitrogen Corporation | Use of multiple recombination sites with unique specificity in recombinational cloning |
EP1111061A1 (en) | 1999-12-20 | 2001-06-27 | Universite Libre De Bruxelles | Double selection vector |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
WO2002012474A2 (de) | 2000-08-03 | 2002-02-14 | Mpb Cologne Gmbh | Verfahren zur selektion auf wirtszellen mit eliminierten dna-sequenzen |
WO2002066657A1 (en) | 2001-02-23 | 2002-08-29 | Universite Libre De Bruxelles | Method for the selection of recombinant clones comprising a sequence encoding an antidote protein to a toxic molecule |
US6528285B1 (en) | 1997-11-06 | 2003-03-04 | Texel | Non RCR leuconostoc plasmid capable of being transferred into lactic acid bacteria, use as cloning and expressing tool |
WO2004022745A2 (en) | 2002-09-03 | 2004-03-18 | Universite Libre De Bruxelles | Reversible, parallel and multitask cloning method and kit |
US20050130308A1 (en) | 1992-07-31 | 2005-06-16 | Philippe Bernard | Cloning and/or sequencing vector |
US20050260585A1 (en) | 2002-03-19 | 2005-11-24 | Cedric Szpirer | Poison/antidote genetic systems for the selection of genetically modified eucaryote cells or organisms |
WO2009011940A2 (en) | 2007-04-06 | 2009-01-22 | University Of Maryland, Baltimore | Microcin h47 plasmid selection system |
WO2010060057A1 (en) | 2008-11-22 | 2010-05-27 | Southern Illinois University Edwarsville | Bacteriocin based methods to control lactic acid bacterial growth |
US20100330041A1 (en) | 2009-05-27 | 2010-12-30 | Bayrock Dennis P | Viral-based antimicrobial agent use in ethanol production |
EP2543255A1 (en) | 2011-07-04 | 2013-01-09 | CSK Food Enrichment B.V. | Anti-listerial mixed culture and method for producing cheese |
US20130115658A1 (en) | 2002-09-03 | 2013-05-09 | Cédric Szpirer | Reversible, parallel and multitask cloning method and kit |
US8476048B2 (en) | 2010-12-17 | 2013-07-02 | E I Du Pont De Nemours And Company | Xylose utilizing zymomonas mobilis with improved ethanol production in biomass hydrolysate medium |
JP2014502501A (ja) | 2010-12-21 | 2014-02-03 | フジフィルム・ダイオシンス・バイオテクノロジーズ ・ユーケイ・リミテッド | 発現プロセス |
US8697426B2 (en) | 2012-06-15 | 2014-04-15 | E I Du Pont De Nemours And Company | Contaminant control in Zymomonas fermentation using virginiamycin |
US20140148379A1 (en) | 2012-11-28 | 2014-05-29 | Mei Liu | Control of Unwanted Bacteria in Fermentation Systems with Bacteriocin |
US20140178956A1 (en) | 2012-12-20 | 2014-06-26 | E I Du Pont De Nemours And Company | Stabilized chlorine dioxide for contamination control in zymomonas fermentation |
US20150050253A1 (en) | 2013-08-19 | 2015-02-19 | Syngulon Sa. | Controlled growth of microorganisms |
WO2019046577A1 (en) | 2017-08-31 | 2019-03-07 | Syngulon Sa | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES |
WO2019121983A1 (en) | 2017-12-19 | 2019-06-27 | Syngulon S.A. | Fermentation process |
WO2019236761A1 (en) | 2018-06-06 | 2019-12-12 | Syngulon Sa | Engineering antimicrobial peptides |
US20220017573A1 (en) | 2018-11-22 | 2022-01-20 | Syngulon S.A. | Peptides for inducing bacteriocin synthesis and methods to identify and/or select and/or optimize the same |
WO2022104321A1 (en) | 2020-11-10 | 2022-05-19 | Syngulon Sa. | Modulating antimicrobial peptide half-life |
WO2022104320A1 (en) | 2020-11-10 | 2022-05-19 | Syngulon Sa. | Control of microorganisms in microbial communities |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997008553A1 (en) * | 1995-08-22 | 1997-03-06 | The Regents Of The University Of California | Targeting of proteins to the cell wall of gram-positive bacteria |
-
2018
- 2018-12-19 JP JP2020535048A patent/JP2021506328A/ja active Pending
- 2018-12-19 CN CN201880088641.3A patent/CN111757890A/zh active Pending
- 2018-12-19 US US16/955,720 patent/US11932672B2/en active Active
- 2018-12-19 BR BR112020012543-1A patent/BR112020012543A2/pt unknown
- 2018-12-19 KR KR1020207020105A patent/KR20200116084A/ko not_active Application Discontinuation
- 2018-12-19 WO PCT/EP2018/085941 patent/WO2019121983A1/en unknown
- 2018-12-19 EP EP18827063.1A patent/EP3728292A1/en active Pending
Patent Citations (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5670370A (en) | 1986-03-26 | 1997-09-23 | Gx Biosystems A/S | Biological containment |
US5631153A (en) | 1989-08-22 | 1997-05-20 | University Of Utah | Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same |
US5300431A (en) | 1991-02-26 | 1994-04-05 | E. I. Du Pont De Nemours And Company | Positive selection vector for the bacteriophage P1 cloning system |
JPH0556790A (ja) | 1991-02-26 | 1993-03-09 | Imperial Chem Ind Plc <Ici> | ベクター、非相同ポリペプチドを表現することのできる宿主、その製法、ポリペプチドの製法及び複製可能なプラスミド表現ベヒクル |
US5910438A (en) | 1992-07-31 | 1999-06-08 | Universite Libre De Bruxelles | Cloning and/or sequencing vector |
WO1994003616A2 (fr) | 1992-07-31 | 1994-02-17 | Universite Libre De Bruxelles | Vecteur de clonage et/ou de sequençage |
US20050130308A1 (en) | 1992-07-31 | 2005-06-16 | Philippe Bernard | Cloning and/or sequencing vector |
US6180407B1 (en) | 1992-07-31 | 2001-01-30 | Universite Libre De Bruxelles | Cloning and/or sequencing vector |
US7176029B2 (en) | 1992-07-31 | 2007-02-13 | Universite Libre De Bruxelles | Cloning and/or sequencing vector |
US5549895A (en) | 1993-05-17 | 1996-08-27 | Iowa State University Research Foundation, Inc. | Method and colicin composition for inhibiting Escherichia coli 0157:H7 in food products |
US5855732A (en) | 1994-11-22 | 1999-01-05 | Nec Corporation | Outer lead bonding apparatus and method of bonding lead to substrate |
US6171861B1 (en) | 1995-06-07 | 2001-01-09 | Life Technologies, Inc. | Recombinational cloning using engineered recombination sites |
US6270969B1 (en) | 1995-06-07 | 2001-08-07 | Invitrogen Corporation | Recombinational cloning using engineered recombination sites |
US6143557A (en) | 1995-06-07 | 2000-11-07 | Life Technologies, Inc. | Recombination cloning using engineered recombination sites |
US5888732A (en) | 1995-06-07 | 1999-03-30 | Life Technologies, Inc. | Recombinational cloning using engineered recombination sites |
WO1997013401A1 (en) | 1995-10-13 | 1997-04-17 | Purdue Research Foundation | Method for the production of hybrid plants |
US5922583A (en) | 1995-10-17 | 1999-07-13 | Biostar Inc. | Methods for production of recombinant plasmids |
WO1997014805A2 (en) | 1995-10-17 | 1997-04-24 | Biostar, Inc. | Methods for production of recombinant plasmids |
WO1999002555A1 (en) | 1997-07-09 | 1999-01-21 | The Governors Of The University Of Alberta | Novel bacteriocins, transport and vector system and method of use thereof |
WO1999021977A1 (en) | 1997-10-24 | 1999-05-06 | Life Technologies, Inc. | Recombinational cloning using nucleic acids having recombination sites |
US6528285B1 (en) | 1997-11-06 | 2003-03-04 | Texel | Non RCR leuconostoc plasmid capable of being transferred into lactic acid bacteria, use as cloning and expressing tool |
US7595186B2 (en) | 1998-05-07 | 2009-09-29 | Université Libre de Bruxelles | Cytotoxin-based biological containment |
US7595185B2 (en) | 1998-05-07 | 2009-09-29 | Université Libre de Bruxelles | Cytotoxin-based biological containment |
WO1999058652A2 (en) | 1998-05-07 | 1999-11-18 | Gx Biosystems A/S | Cytotoxin-based biological containment |
US7183097B1 (en) | 1998-05-07 | 2007-02-27 | Universite Libre De Bruxelles | Cytotoxin-based biological containment |
US6271359B1 (en) | 1999-04-14 | 2001-08-07 | Musc Foundation For Research Development | Tissue-specific and pathogen-specific toxic agents and ribozymes |
WO2001031039A1 (en) | 1999-10-25 | 2001-05-03 | Invitrogen Corporation | Methods of manipulating and sequencing nucleic acid molecules using transposition and recombination |
WO2001042509A1 (en) | 1999-12-10 | 2001-06-14 | Invitrogen Corporation | Use of multiple recombination sites with unique specificity in recombinational cloning |
WO2001046444A1 (en) | 1999-12-20 | 2001-06-28 | Universite Libre De Bruxelles | Double selection vector |
EP1111061A1 (en) | 1999-12-20 | 2001-06-27 | Universite Libre De Bruxelles | Double selection vector |
WO2002012474A2 (de) | 2000-08-03 | 2002-02-14 | Mpb Cologne Gmbh | Verfahren zur selektion auf wirtszellen mit eliminierten dna-sequenzen |
DE10038573A1 (de) | 2000-08-03 | 2002-02-21 | Mpb Cologne Gmbh Molecular Pla | Verfahren zur Selektion auf Wirtszellen mit eliminierten DNA-Sequenzen |
US20040115811A1 (en) | 2001-02-23 | 2004-06-17 | Philippe Gabant | Method for the selection of recombination clones comprising a sequence encoding an antidote protein to a toxic molecule |
US8470580B2 (en) | 2001-02-23 | 2013-06-25 | Universite Libre De Bruxelles | Method for the selection of recombination clones comprising a sequence encoding an antidote protein to a toxic molecule |
US20130280810A1 (en) | 2001-02-23 | 2013-10-24 | Universite Libre De Bruxelles | Method for the selection of recombinant clones comprising a sequence encoding an antidote protein to toxic molecule |
US8877504B2 (en) | 2001-02-23 | 2014-11-04 | Universite Libre De Bruxelles | Method for the selection of recombinant clones comprising a sequence encoding an antidote protein to toxic molecule |
WO2002066657A1 (en) | 2001-02-23 | 2002-08-29 | Universite Libre De Bruxelles | Method for the selection of recombinant clones comprising a sequence encoding an antidote protein to a toxic molecule |
US20050260585A1 (en) | 2002-03-19 | 2005-11-24 | Cedric Szpirer | Poison/antidote genetic systems for the selection of genetically modified eucaryote cells or organisms |
US8318497B2 (en) | 2002-09-03 | 2012-11-27 | Universite Libre De Bruxelles | Reversible, parallel and multitask cloning method and kit |
US20130115658A1 (en) | 2002-09-03 | 2013-05-09 | Cédric Szpirer | Reversible, parallel and multitask cloning method and kit |
WO2004022745A2 (en) | 2002-09-03 | 2004-03-18 | Universite Libre De Bruxelles | Reversible, parallel and multitask cloning method and kit |
WO2009011940A2 (en) | 2007-04-06 | 2009-01-22 | University Of Maryland, Baltimore | Microcin h47 plasmid selection system |
WO2010060057A1 (en) | 2008-11-22 | 2010-05-27 | Southern Illinois University Edwarsville | Bacteriocin based methods to control lactic acid bacterial growth |
US20100330041A1 (en) | 2009-05-27 | 2010-12-30 | Bayrock Dennis P | Viral-based antimicrobial agent use in ethanol production |
US8476048B2 (en) | 2010-12-17 | 2013-07-02 | E I Du Pont De Nemours And Company | Xylose utilizing zymomonas mobilis with improved ethanol production in biomass hydrolysate medium |
JP2014502501A (ja) | 2010-12-21 | 2014-02-03 | フジフィルム・ダイオシンス・バイオテクノロジーズ ・ユーケイ・リミテッド | 発現プロセス |
EP2543255A1 (en) | 2011-07-04 | 2013-01-09 | CSK Food Enrichment B.V. | Anti-listerial mixed culture and method for producing cheese |
US8697426B2 (en) | 2012-06-15 | 2014-04-15 | E I Du Pont De Nemours And Company | Contaminant control in Zymomonas fermentation using virginiamycin |
US20140148379A1 (en) | 2012-11-28 | 2014-05-29 | Mei Liu | Control of Unwanted Bacteria in Fermentation Systems with Bacteriocin |
US20140178956A1 (en) | 2012-12-20 | 2014-06-26 | E I Du Pont De Nemours And Company | Stabilized chlorine dioxide for contamination control in zymomonas fermentation |
US11427800B2 (en) | 2013-08-19 | 2022-08-30 | Syngulon Sa | Controlled growth of microorganisms |
US20150050253A1 (en) | 2013-08-19 | 2015-02-19 | Syngulon Sa. | Controlled growth of microorganisms |
US9333227B2 (en) | 2013-08-19 | 2016-05-10 | Syngulon Sa. | Controlled growth of microorganisms |
US10188114B2 (en) | 2013-08-19 | 2019-01-29 | Syngulon Sa | Controlled growth of microorganisms |
US20230193191A1 (en) | 2013-08-19 | 2023-06-22 | Syngulon Sa | Controlled growth of microorganisms |
WO2019046577A1 (en) | 2017-08-31 | 2019-03-07 | Syngulon Sa | METHODS AND COMPOSITIONS FOR THE PRODUCTION OF BACTERIOCIN AND ANTIMICROBIAL PEPTIDES |
US11492651B2 (en) | 2017-08-31 | 2022-11-08 | Syngulon Sa | Methods and compositions for making bacteriocins and antimicrobial peptides |
WO2019121983A1 (en) | 2017-12-19 | 2019-06-27 | Syngulon S.A. | Fermentation process |
WO2019236761A1 (en) | 2018-06-06 | 2019-12-12 | Syngulon Sa | Engineering antimicrobial peptides |
US20210238645A1 (en) | 2018-06-06 | 2021-08-05 | Syngulon Sa. | Engineering antimicrobial peptides |
US20220017573A1 (en) | 2018-11-22 | 2022-01-20 | Syngulon S.A. | Peptides for inducing bacteriocin synthesis and methods to identify and/or select and/or optimize the same |
WO2022104320A1 (en) | 2020-11-10 | 2022-05-19 | Syngulon Sa. | Control of microorganisms in microbial communities |
WO2022104321A1 (en) | 2020-11-10 | 2022-05-19 | Syngulon Sa. | Modulating antimicrobial peptide half-life |
Non-Patent Citations (145)
Title |
---|
(1992) Journal of Cellular Biochemistry, Keystone Symposia on Molecular & Cellular Biology, 104. |
Abremski, et al. (1984) Bacteriophage P1 Site-specific Recombination. J. Bio. I. Chem. 259(3):1509-1514. |
Acuna, et al., FEBS Open Bio, 2: 12-19, 2012. |
Adetunji and Olaoye, Malaysian Journal of Microbiology 9: 130-13, 2013. |
Aizenman, et al. (1996) An Escherichia coli chromosomal "addiction module" regulated by 3′, 5′-bispyroohosohate: A modayk for programmed bacterial cell death. Proc. Nail. Acad. Sci. 93:6059-6063. |
Allison et al., Functional analysis of the Gene Encoding Immunity to Lactacin F, lafi, and its use as a Lactobacillus-Specific, Food-Grade Genetic Marker, Applied and Environmental Microbiology, vol. 62, No. 12, pp. 4450-4460, 1996. |
Altschul, S.F., et al., "Basic local alignment search tool", J. Mol. Biol. 215:403-410, 1990. |
Backman, et al., (1983), "Tetracycline Resistance Determined by pBR322 is Mediated by one Polypeptide." Gene 26. pp. 197-203. |
Bacteriocin, Wikipedia, http://en.wikpedia.org/wiki/Bacteriocin Printed on Oct. 3, 2014. |
Bahassi, et al. (1995) F plasmid CcdB killer protein: ccd8 gene mutants coding for non-cy1otoxic proteins which retain their regulatory functions. Molecular Microbiology 15(6:1031-1037. |
Bahassi, et al. (1995) F plasmid CcdB killer protein: ccd8 gene mutants coding for non-cy1otoxic proteins which retain their regulatory functions. Molecular Microbiology 15(6\:1031-1037. |
Basanta, A. et al. Developement of Bacteriocinogenic Strains of Saccharomyces cerevisiae Heterologously Expressing and Secreting the Leaderless Enterocin L50 Peptides L50A and L50B fro1n Enterococcz1s faeciurn L50, Applied And Environmental Microbiology, vol. 75, No. 8 p. 2382-2392, 200. |
Baum, "Tn5401, a New Class II Transposable Element from Bacillus thuringiensis," Journal of Bacteriology, vol. 176. No. 10, May 1994, pp. 2835-2845. |
Baunonis, et al. (1993) Genomic Targeting with Purified Cre Recombinase. Nucleic Acids Research 21 (9):2025-2029. |
Bech et al., "Sequence of the reLB transcription unit from Escherichia coli and Identification of the reLB gene," The EMBO Journal, vol. 4, No. 4 00.1059-1066 1985. |
Bernard (1996) Positive Selection of Recombinant DNA by CcdB. BioTechniques 21(2)320-323. |
Bernard et al., 1992 "Cell killing, by the F plasmid CcdB protein involves poisoning of DNA-topoisomerase II complexes," J. Mol. Biol. 226:735-745. |
Bernard, et al. (1991) The 41 carboxy-terminal residues of the miniF plasmid CcdA protein are sufficient to antagonize the killer activity of the CcdB protein. Mol. Gen Genet 226:297-304. |
Bernard, P., et al. (1994) Positive-Selection Vectors Using the F Plasmid cedB Killer Gene. Gene 148, pp. 71-74. |
Bex, et al. (1983) Mini-F encoded proteins: identification of a new 10.5 kilodalton species. The EMBO Journal,2(11):1853-1861. |
Biswas, et al. (1993) High-Efficiency Gene Inactivation and Replacement System for Gram-Positive Bacteria. J. Bacteriology 175(11):3628-3635. |
Bochner, et al. (1980) Positive Selection for loss of Tetracycline Resistance. J. Bacteriology 143(2):923-933. |
Borrero J. et al., Cloning, Production, and Functional Expression of the Bacteriodn Enterocin A, Produced by Enterococcus faecium 'TI 36, by the Yeasts Pichia pastoris, Kluyveromyces lactis, Flansenula polyn1orpha, and Arxula adeninivorans, Applied and Environmental Mkrobiology, vol. 78, No. 16, p. 5956-5961, 2012. |
Boyd (1993) Turbo Cloning: A Fast, Efficient Method for Cloning PCR Products and Other Blunt-Ended DNA Fragments into Plasmids. Nucleic Acids Research 21(4):817-821. |
Bravo, et al. (1988) Killing of Escherichia coli cells modulated by components of the stability system ParD of plasmid R1. Mol. Gen. Genet. 215:146-151. |
Brede et al., Identification Of The Propionicin F Bacteriocin Immunity Gene (Pcfi) And Development Of A Food0Grade Cloning System For Propionibacterium Freudenreichii, Applied And Environmental Microbiology, vol. 73, No. 23, pp. 7542-7547, 2007. |
Bubeck, et al. (1993) Rapid Cloning by Homologous Recombination in vivo. Nucleic Acids Research 21(15):3601-3602. |
Bult, "Complete Genome Sequence of the Methanogenic Archaeon, Methanococcus jannaschii," Science, vol. 273 Aug. 23, 1996.00.1058-1073. |
Burns, et al. (1984) Positive Selection Vectors: A Small Plasmid Vector Useful for the Direct Selection of Sau2A-aenerated overlapping DNA Fragments. Gene 27:323-325. |
Campelo et al., "A bacteriocin gene cluster able to enhance plasmid maintenance in Lactococcus lactis", Microbial Cell Factories 2014, 13:77. Accessible on the world wide web at www.microbialcellfactories.com/content/13/1/77. 9 oaqes. |
Cole et al., "Deciphering the Biology of Mycobacterium tuberculosis from the Complete Genome Sequence," Nature vol. 393, Jun. 11, 1998 Do.537-544. |
Cotter, P. D. et al., "Bacteriocins-a viable alternative to antibiotics", Nature Reviews Microbiology 11:95-105, 2013. |
Couturier, et al. (1998) Bacterial death by DNA gyrase poisoning. Trends in Microbiology 6(7):269-275. |
Craine, (1982) Novel Selection for Tetracycline-or Chloramphenicol-Sensitive Escherichia coli. J. Bacteriology 151(1):487-490. |
Cui et al., "Class IIa Bacteriocins: Diversity and New Developments", Int. J. Mol. Sci., vol. 13, pp. 16668-16707, 2012. |
Daw et al., "Bacteriocins: Nature, Function and Structure", Micron, vol. 27, No. 6, pp. 467-479, 1996. |
D'Souza, S.F., "Microbial biosensors", Biosensors & Bioelectronics, vol. 16, 2001, pp. 337-353. |
Duquesne et al., Microcins, Gene-Encoded Antibacterial Peptides From Enterobacteria, The Journal Of The Royal Society Of Chemistry, vol. 24, pp. 708-734, 2007. |
Ebert et al. "A Moloney MLV-Rat Somatotropin Fusion Gene Produces Biologically Active Somatotropin in a transgenic pig." Molecular Endocrinology. 2:277-283, 1988. |
Fang et al., Use of mchl Encoding Immunity to the antimicrobial peptide microcin H47 as a Plasmid Selection Marker in Attenuated Bacterial Live Vectors, Infection and Immunity, vol. 76, No. 10, pp. 4422-4430, 2008. |
Fleischmann et al., "Whole-Genome Random Sequencing and Assembly of Haemophilus Influenza Rd," Science, Vo1.269. 00.496-512 Jul. 28, 1995. |
Gabant et al., 1997 "Bifunctional lacZ a-ccdB genes for selective cloning of PCR products," Biotechniques 23:938-941. |
Gabant et al., 1998 "Direct selection cloning vectors adapted to the genetic analysis of gram-negative bacteria and their plasmids," Gene 207:87-92. |
Gabant et al., 2000 "New positive selection system based on the parD (kislkid) system of the R1 plasmid," Biotechniques 28:784-788. |
Gabant et al., 2001 "Use of poison/antidote systems for selective cloning," in Plasmid Biology 2000: International, Symposium on Molecular Bioloy of Bacterial Plasmids, Meeting Abstracts, 00.135-170, Plasmid 45:160-161. |
Gajic et al., "Novel Mechanism of Bacteriocin Secretion and Immunity Carried Out by Lactococcal Multidrug Resistance Proteins*", The Journal of Biological Chemistry, Sep. 5, 2003, vol. 278, No. 36, DD. 34291-34298. |
Gerard et al., Bactericidal Activity of Colicin V Is Mediated by an Inner Membrane Protein, SdaC, of Escherichia coli, Journal Of Bacteriology, vol. 187, No. 6, pp. 1945-1950, Mar. 2005. |
Gerdes (2000) Toxin-Antitoxin modules may regulate synthesis of macromolecules during nutritional stress. Journal of Bacteriology 182:561-572. |
Gerdes, et al. "RNA antitoxins." (2007) Current Opinion in Microbiology, vol. 10, p. 117-124. |
Gibson et al., "Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome", Science, vol. 329, pp. 52-56, 2010. |
Goni-Moreno, et al., "Multicellular Computing Using Conjugation for Wiring", PLoS One 8(6): e65986, 2013. |
Gossen, J. A., et al. (1992) Application of Galactose-Sensitive E.coli Strains as Selective Hosts for LacZ Plasmids. Nucleic Acids Res. 20.0.3254. |
Gotfredsen, et al., "The Escherichia coli relBE genes belong to a new toxin-antitoxin gene family" Molecular Microbiology (1998) 29(4): 1065-1076. |
Green and Sambrook, "Molecular Cloning: a Laboratory Manual", Cold Spring Harbor Laboratory Press; 4th edition, 2012. |
Gronenborn (1978) Methylation of single-stranded DNA in vitro introduces new restriction endonuclease cleavage sites. Nature, 272:375-377. |
Gronlund et al., "Toxin-Antitoxin Systems Homologous with relBE of Escherichia coli Plasmid P307 are Ubiquitous in Prokaryotes," Journal of Molecular Biology, Vo1.285, No. 4, Jan. 29, 1999, pp. 1401-1415. |
Guilfoyle, R.A., and I.M. Smith (1994) "A Direct Selection Strategy for Stotgun Cloning and Sequencing in the Bacteriophage M13." Nucleic Acids Res.22, pp. 100-107. |
Guzman et al. 1995 "Tight regulation, modulation, and high-level expression by vectors containing the arabinose PBAO promoter," J. Bacteriol. 177:4121-4130. |
Hammer et al. "Genetic Engineering of Mammalian Embryos." J. Anim. Sci. 63:269-278, 1986. |
Hartley et al., DNA cloning using in vitro site-specific recombination: Genome Res. 10:1788-1795, 2000. |
Hasan et al., Gene, vol. 56, pp. 145, 1987. |
Hebsgaard, S.M., et al. (1996) "Splice Site Prediction in Arabidopsis thaliana Pre-mRNA by Combining Local and Global Sequence information." Nucleic Acids Research, 24(17) 3439-3452. |
Henrich et al. 1986 "Use of the lysis gene of bacteriophage X174 for the construction of a positive selection vector," Gene 42:345-349. |
Herrero, M., et al., (1990) "Transposon Vectors Containing Non-Antibiotic Resistance Selection markers for Cloning and Stable Chromosomal Insertion of Foreign Genes in Gram-Negative Bacteria." J. Bact. 172,11, pp. 6557-6567. |
Holt, et al. (1993) A Novel Phage λ Replacement Cre-lox Vector that has Automatic Subcloning Capabilities, Gene 133:95-97. |
Inglis, et al., "The Role of Bacteriocins as Selfish Genetic Elements". Biology Letters, Issue 9, vol. Jun. 3, 2013. Published Apr. 24, 2013, DOI: 10.1098/rsbl.2012.1173. 6 pages. |
International Search Report and Written Opinion dated Mar. 11, 2019 in International Application No. PCT/EP2018/085941. |
Ioannou, et al. (1994) A new bacteriophage P1-derived vector for the propagation of large human DNA fragments, Nature Genetics 6:84-89. |
Jaramillo, A., "Synthetic Biology—Engineered stable ecosystems". Nature Microbiology, vol. 2, No. 17119, pp. 1-2, Jul. 25, 2017. |
Jensen et al., 1995 "Comparison of ccd of F, parDE of RP4, and parD of R1 using a novel conditional replication control system of plasmid R1," Molecular Microbiology 17:211-220. |
Jensen et al., 1995 Programmed cell death in bacteria: protect plasmid stabilization systems, Molecular Microbiology 17:205-210. |
Kaneko et al., "Sequence Analysis of the Genome of the Unicellular Cyanobacterium synechocystis sp. Strain PCC6803. II. Sequence Determination of the Entire Genome and Assignment of Potential Protein-Coding Regions " DNA Research, vol. 3, 00.109-136.1996. |
Karoui, et al. (1983) Ham22, a mini-F mutation which is lethal to host cell and promotes recA-dependent induction of lambdoid prophage. The EMBO Journal. 2(11): 1863-1868. |
Kobayashi, M., et al., Promoter selectivity of Escherichia coli RNA polymerase: effect of base substitutions in the promoter-35 region on promoter strength. Nucleic Acids Res. 18:7367-7372, 1990. |
Kristoffersen et al. "Bacterial Toxin-Antitoxin Gene Systems as Containment Control in Yeast Cells" Applied and Environmental Microbiology, vol. 66 No. 12, Dec. 2000, p. 5524-5526. |
Kuhn et al. 1986 "Positive-selection vectors utilizing lethality of the EcoRI endonuclease," Gene 44:253-263. |
Landy, Arthur, 1989 Dynamic, structural, and regulatory aspects of A site-specific recombination: Annu. Rev. Biochem 58:913-949. |
Lehnherr, et al. (1993) Plasmid Addiction Genes of Bacteriophage P1: doc, which cause cell death on curing of prophage, and phd, which prevents host death when prophage is retained. J. Mol. Biol. 233:414-428. |
LIU (1989) DNA Topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 58:351-375. |
Maki, et al.(1992) Modulation of DNA Supercoiling Activity of Escherichia coli DNA Gyrase by F Plasmid Proteins, The Journal of Biological Chemistry vol. 267(17):12244-12251. |
Maloy, et al. (1981) Selection for Loss of Tetracycline Resistance by Escherichia coli, Journal of Bacteriology, 145(2):1110-1112. |
Manning, P.A., "Nucleotide Sequence encoding the Mannose-fucose-resistant Hemagglutinin of Vibrio Cholerae 01 and Construction of a Mutant," EMBL Sequence Database, Aug. 7, 1993. pp.1-7. |
Maxwell, et al. (1986) Mechanistic aspects of DNA Topoisomerases. Advan. Protein Chem. 38:69-107. |
McAuliffe et al., "Identification and overexpression of Itnl, a novel gene which confers immunity to the two-component lantibiotic lacticin 3147", Microbiology, 2000, vol. 146, pp. 129-138. |
McBride, et al., "Contamination management in Low Cost Open Algae Ponds for Biofuels Production", Industrial Biotechnology, vol. 10, pp. 221-227, 2014. |
Messing, et al. (1977) Filamentous coliphage M13 as a cloning vehicle: Insertion of a HindII Fragment of the lac regulatory region in M13 replicative form in vitro. Proc Nail. Acad. Sci. 74(9):3642-3646. |
Miki, et al. (1984) Control of Cell Division by Sex Factor F in Escherichia coli. J. Mol. Bioi. 174:627-646. |
Moreadith et al. "Gene Targeting in Embryonic Stem Cells: The new Physiology and metabolism." J. Mol. Med. 75:208-216 1997. |
Mori, Hirotada, et al., "Prophage A Induction Caused by Mini-F Plasmid Genes." (1984) Mol Gen Genet 196:185-193. |
Mullins et al. "Perspective Series: Molecular Medicine in Genetically Engineered Animals." J. Clin. Invest. 98 (Suppl.): 837-S40, 1996. |
Murphy, et al. (1991), pAZd39: A New Type of cDNA Expression Vector for Low Background, High Efficiency Directional Cloning. Nucleic Acids Research 19(12):3403-3408. |
Muyrers et al. 2001 "Techniques: recombinogenic engineering—new 'options for cloning and manipulating DNA," Trends in Biochem. Sci. 26:325-331. |
Nilsson, et al. (1983) An Improved Positive Selection Plasmid Vector Constructed by Oligonucleotide Mediated Mutagenesis. Nucleic Acids Research 11 (22):8019-8029. |
Nomura M., "Colicins and Related Bacteriocins", Annual Review of Microbiology, vol. 21, pp. 257-284, Oct. 1967. |
Norrander, et al. (1983) Construction of improved M13 vectors using oligodeoxynucleotide-directed mutagenesis. Gene 26:101-106. |
Office Action with English Translation in Japanese Patent Application No. 2020-535048, dated May 17, 2023 in 19 pages. |
Ogura, et al. (1983) Mini-F plasmid genes that couple host cell division to plasmid proliferation. Proc. Natl. Acad. Sci. USA 80:4784-4788. |
Opinion of the Scientific Panel on Food Additives, Flavourings, Processing Aids and Materials in Contact with Food on a Request from the Commission Related to the use of Nisin (E 234) as a food additive. Question No. EFSA-Q-2005-031. Adopted on Jan. 26, 2006. The EFSA Journal (2006) 314, pp. 1-16. |
Pag et al., "Molecular Analysis of Expression of the Lantibiotic Pep5 Immunity Phenotype", Applied and Environmental Microbiology, Feb. 1999, vol. 65, No. 2, pp. 591-598. |
Peakman, et al. (1992) Highly Efficient Generation of Recombinant Baculoviruses by Enzymatically Mediated Site-Specific in vitro Recombination. Nucleic Acids Research 20(3):495-500. |
Pecota, et al. "Combining the hok/sok, parDE, and pnd Postsegregational Killer Loci to Enhance Plasmid Stability." (1997) Applied and Environmental Microbiology, vol. 63, p. 1917-1924. |
PGT-N28 Vector DNA (catalog #N3728) New England Biolabs Online Catalog, Jun. 2, 1999, p. 1, www.neb.comlneb/products/nucleicJ307-28.html the whole document. |
Pierce et al. 1992 "A positive selection vector for cloning high molecular weight DNA by the bacteriophage P1 system: improved cloning efficacy," PNAS USA 89:2056-2060. |
PKO Scrambler Series Gene Targeting Vectors for Knockout Mice. Stratagene Online Catalog, Jan. 1998, pp. 1-3; www.stratagene.com/cellbio/toxicology/pko.htm, the whole document. |
Pomares et al., "Potential Applicability of Chymotrypsin-Susceptible Microcin J25 Derivatives to Food Preservation", Applied and Environmental Microbiology, vol. 75, No. 17, pp. 5734-5738, Sep. 2009. |
Reeves et al., Engineering Escherichia coli into a Protein Delivery Systemn for Mammalian Cells ACS Synth. Biol. 2015, 4 ,644-654. |
Riley et al., "Bacteriocins: Evolution, Ecology, and Application", Annu. Rev. Microbiol., 2002, vol. 56, pp. 117-137. |
Roberts, et al. (1992) Definition of a Minimal Plasmid Stabilization System from the Broad-Host-Range Plasmid RK2. Journal of Bacteriology Dec. 1992:8119-8132. |
Roberts, et al. (1994) The parDE operon of the broad-host-range plasmid RK2 specifies growth inhibition associated with plasmid loss. J. Mol. Biol. 18; 237 (1): 35-51. |
Roca, et al. (1992) A Hit-and-Run System for Targeted Genetic Manipulations in Yeast. Nucleic Acid Research 20(17):4671-4672. |
Ruiz-Echevarria et al. (1991) Structural and functional comparison between the stability systems ParD of plasmid R1 and Ccd of plasmid. F. Mol. Gen. Genet 225:355-362. |
Ruiz-Echevarria et al. 1995 A mutation that decreases the efficiency of plasmid R1 replication leads to the activation of parD, a killer stability system of the plasmid: FEMS Microb. Letters 130: 129-136. |
Ruiz-Echevarria, et al. (1991) The kis and kid genes of the parD maintenance system of plasmid R1 form an operon that is autoregulated at the level of transcription by the co-ordinated action of the Kis and Kid proteins. Molecular Microbiology 5(11):2685-2693. |
Sadler, et al. (1980) Plasmids containing many tandem copies of a synthetic lactose operator. Gene 8:279-300. |
Salmon et al., "The Antidote and Autoregulatory Functions of the F Plasmid CcdA Protein: a Genetic and biochemical Survey" Molecular and General Genetics vol. 244, pp. 530-538. 1994. |
Sambrook, et al. (1989) Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 4.12 A.9-A.13. |
Saul, et al., "Nucleotide Sequence and Replication Characteristics of RepFIB, a Basic Replicon of IncF Plasmids," Journal of Bacteriology. vol. 171 No. 5 00.2697-2707, May 1989. |
Schlieper et al. 1998 "A positive selection vector for cloning of long polymerase chain reaction fragments based on a lethal mutant of the crp gene of Escherichia coli," Anal. Biochem. 257:203-209. |
Schoeman, H. et al., the Development of Bactericidal Yeast Strains by Expressing the Pediococcus acidilactici Pediocin Gene (pedA) in Saccharo1nyces cerevisiae, Yeast, vol. 15, 647-656, 1999. |
Seamark R.F. "Progress and Emerging Problems in Livestock Transgenesis: a Summary perspective." Repod. Fert. Dev. 6:653-657, 1994. |
Shalani and Srivastava (2008) The Internet Journal of Microbiology. vol. 5 No. 2. DOI: 10.5580127dd—accessible on the worldwide web at archive.ispub.comljournallthe-internet-journal-of-microbiology/volume-5-number-2/screening-for-antifungal-activity-of-pseudomonas-fluorescens-against-phytopathogenic-fungi.html#sthash.dOYs03UO.1DKuT1US.dpuf. |
Shekh and Roy, BMC Microbiology 12: 132, 2012. |
Shenin et al., "Characteristics of Alirin B1, the major component of a fungicidal substance produced by Bacillus subtilis 10-VIZR". Antibiot Khimioter 1995 vol. 50: pp. 3-7. |
Sierra et al. 1998 "Functional interactions between chpB and parD, two homologous conditional killer systems found in the Escherichia coli chromosome and in plasmid R1," FEMS Microb. Letters 168:51-58. |
Simons, R. W., et al. (1987) "Improved Single and Multicopy Lac-Based Cloning Vectors for Protein and Operon Fusions." Gene 53 Do.85-96. |
Smith, et al. (1985) Modification and Selection of Human Interleukin 2 Produced in Insect Cells by Baculovirus Expression Vector. Nalt Acad. Sci. 82:8404-8408. |
Smith, et al. (1997) The poison-antidote stability system of the broad-host-range Thiobacilus ferroxidans plasmid pTF-FC2. Molecular Microbioloav 26(5):961-970. |
Takala et al., A Food-Grade Cloning Vector For Lactic Acid Bacteria Based On The Nisin Immunity Gene nisl, Appl Microbiology Biotechnology, vol. 59, pp. 467-471, 2002. |
Thisted, et al., "Mechanism of Post-segregational Killing by the hok/sok System of Plasmid R1; Sok Antisense RNA Regulates hok Gene Expression Indirectly Through the Overlapping mok Gene." (1992) J. Mol. Biol., vol. 223, p. 41-54. |
Tomb et al., "The Complete Genome Sequence of the Gastric Pathogen Helicobacter Pylori," Nature. vol. 388 Aug. 7, 1997 pp. 539-547. |
Trudel et al., (1996), pGATA: a positive selection vector based on the toxicity of the transcription factor GATA-1 to bacteria: BioTechniques 20:684-693. |
Tsuchimoto et al. (1988) Two Genes, pelK and peml, responsible for stable maintenance of resistance plasmid R100. J. of Bateriol., 170(4):1461-1466. |
Tsuchimoto et al., "The Stable Maintenance System pem of Plasmid R100: Degradation of Peml Protein May Allow PemK Protein To Inhibit Cell Growth." Journal of Bacteriology, vol. 174, No. 13, pp. 4205-4211 Jul. 1992. |
Tsuchimoto, et al. (1993) Autoregulation by cooperative binding of the Peml and PemK proteins to the promoter region of the pem operon. 237:81-88. |
Union Nationale des Groupements de Distillateurs D'Alcool, "Kamoran", 2005. |
Van Melderen, et al., "Bacterial Toxin-Antitoxin Systems: More Than Selfish Entities?", PLoS Genetics, vol. 5, No. 3, Mar. 2009, pp. 1-6. |
Van Reeth, T., et al. (1998) "Positive Selection Vectors to Generate Fused Genes for the Expression of His-Tagged Proteins." BioTechniques. 25(5):898-904. |
Vernet, T., et al. (1985) "A Direct-Selection Vector Derived from pColE3-CA38 and adapted for Foreign Gene Expression." Gene 34:87-93. |
Wang et al., Genome Mining Demonstrates the Widespread Occurrence of Gene Clusters Encoding Bacteriocins in Cyanobacteria. PLoS One 6(7): e22384, 2011. |
Wang, (1985), DNA Topoisomerases. Ann. Rev. Biochem. 54:665-697. |
Wright et al., "Building-in biosafety for synthetic biology", Microbiology, vol. 159, pp. 1221-1235, 2013. |
Yanisch-Perron, et al. (1985) Improved M13 phage closing vectors and host strains: Nucleotide sequence of the M13mp18 and DUC19 vectors. Gen, 33:103-119. |
Yarmolinsky (1995) Programmed cell death in bacterial populations. Science, 267:836-837. |
Yu et al. 2000 "An efficient recombination system for chromosome engineering in Escherichia coli," PNAS USA 97:5978-5983. |
Zuber, P et al., "Peptide Antibiotics", in Sonenshein ed, "Bacillus subtilis and Other Gram-Positive Bacteria", 1993 American Society for Microbiology, Washington D.C. pp. 897-916. |
Also Published As
Publication number | Publication date |
---|---|
EP3728292A1 (en) | 2020-10-28 |
US20210070812A1 (en) | 2021-03-11 |
JP2021506328A (ja) | 2021-02-22 |
CN111757890A (zh) | 2020-10-09 |
WO2019121983A1 (en) | 2019-06-27 |
BR112020012543A2 (pt) | 2021-02-23 |
KR20200116084A (ko) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11932672B2 (en) | Fermentation process | |
US10188114B2 (en) | Controlled growth of microorganisms | |
Masuda et al. | Identification and characterization of leucocyclicin Q, a novel cyclic bacteriocin produced by Leuconostoc mesenteroides TK41401 | |
Abdullah-Al-Mahin et al. | Improvement of multiple-stress tolerance and lactic acid production in Lactococcus lactis NZ9000 under conditions of thermal stress by heterologous expression of Escherichia coli dnaK | |
Callewaert et al. | Characterization and production of amylovorin L471, a bacteriocin purified from Lactobacillus amylovorus DCE 471 by a novel three-step method | |
Steiner et al. | An agr quorum sensing system that regulates granulose formation and sporulation in Clostridium acetobutylicum | |
Abriouel et al. | Diversity and applications of Bacillus bacteriocins | |
Yim et al. | Isolation of fully synthetic promoters for high‐level gene expression in Corynebacterium glutamicum | |
Anné et al. | Protein secretion biotechnology in Gram-positive bacteria with special emphasis on Streptomyces lividans | |
Masuda et al. | Characterization and identification of weissellicin Y and weissellicin M, novel bacteriocins produced by Weissella hellenica QU 13 | |
Badoei-Dalfard et al. | Screening and isolation of an organic solvent tolerant-protease from Bacillus sp. JER02: Activity optimization by response surface methodology | |
Diep et al. | Data mining and characterization of a novel pediocin-like bacteriocin system from the genome of Pediococcus pentosaceus ATCC 25745 | |
EP3380496B1 (en) | Enhanced protein production and methods thereof | |
Meng et al. | Expression of a novel bacteriocin—the plantaricin Pln1—in Escherichia coli and its functional analysis | |
US20200181595A1 (en) | Bacillus Licheniformis Host Cell | |
Chen et al. | Cloning and heterologous expression of a bacteriocin sakacin P from Lactobacillus sakei in Escherichia coli | |
Kim et al. | Identification and characterization of a bacteriocin produced by an isolated Bacillus sp. SW1-1 that exhibits antibacterial activity against fish pathogens | |
US20220348615A1 (en) | Production of bacteriocins | |
Promchai et al. | Rapid production of extracellular thermostable alkaline halophilic protease originating from an extreme haloarchaeon, Halobacterium salinarum by recombinant Bacillus subtilis | |
EP3555320B1 (en) | Methods and strain | |
Liu et al. | The yajC gene from Lactobacillus buchneri and Escherichia coli and its role in ethanol tolerance | |
US10273490B2 (en) | Erythritol production in cyanobacteria | |
EP3883949A1 (en) | Peptides for inducing bacteriocin synthesis and methods to identify and/or select and/or optimize the same | |
Miller et al. | Mechanism for temperature-dependent production of piscicolin 126 | |
Weixler | Establishment of Corynebacterium glutamicum for the heterologous production of bacteriocins |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
FEPP | Fee payment procedure |
Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |
|
AS | Assignment |
Owner name: UNIVERSITE LIBRE DE BRUXELLES, BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:VAN MELDEREN, LAURENCE;REEL/FRAME:053447/0235 Effective date: 20200729 Owner name: SYNGULON S.A., BELGIUM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GABANT, PHILIPPE;EL BAKKOURY, MOHAMED;REEL/FRAME:053447/0789 Effective date: 20200729 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: ADVISORY ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT RECEIVED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |